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Abstract 
Gonadotropin-releasing hormone (GnRH-I), as well as its receptor, GnRHR-I, once 
thought to be localized solely to the hypothalamus and anterior pituitary, have since been 
detected in the testis of numerous mammals. Another isoform of GnRH, GnRH-II, has been 
isolated from the testis of numerous mammals and binds a specific receptor, GnRHR-II. Our 
objective was to establish whether GnRH-I and GnRH-II, along with their specific receptors, are 
produced and present in the equine testis. Testicular tissue was collected from colts < 2 yr (n = 5) 
and stallions ≥ 2 yr (n = 10) of age during routine castrations. Total RNA extracted from 
testicular tissue was reverse transcribed and cDNA was subjected to conventional PCR using 
gene specific primers for GnRH-I, GnRHR-I, GnRH-II, and GnRHR-II. Protein was extracted 
and subjected to dot blot and Western blot using antibodies directed against GnRH-I, GnRH-II, 
GnRHR-I, or GnRHR-II. Transcripts for both ligands and receptors were detected in all testes. 
Product identity was confirmed by sequencing, which also clarified that unusual band sizes were 
the result of alternative splicing of GnRHR-II, and the retention of an intron in the GnRH-II 
mRNA was discovered. Prepro-GnRH-I and prepro-GnRH-II protein was detected in all stallion 
testes via dot blot technique. On Western blots, testicular samples from colts (n = 4) had 3-fold 
greater GnRHR-I levels compared to stallions (n = 7; P < 0.022). Conversely, there was a 
tendency for GnRHR-II protein to be greater in tissue collected from stallions compared to colts 
(P < 0.0756). Finally semen was collected from mature stallions (9 to 18 yr; n = 4) and purified 
using a discontinuous gradient. By utilizing immunocytochemistry, GnRHR-II was localized to 
the connecting piece of mature stallion spermatozoa. This is the first report identifying GnRH-I 
and -II and their receptors in the equine testis and GnRHR-II on mature stallion spermatozoa. 
  
These decapeptide hormones may act via autocrine and/or paracrine signaling to affect 
steroidogenesis and spermatogenesis in the stallion testis.  
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Chapter 1 - Hormonal Regulation of Stallion Reproduction 
An intricate network of hormonal signaling, known as the hypothalamo-pituitary-testis 
axis, tightly regulates stallion reproduction (Roser, 2008). The hypothalamus, pituitary, and 
testicles communicate through endocrine, paracrine, and autocrine signaling mechanisms (Figure 
1.1). The hypothalamus is the neural control center for reproduction and is regulated via positive 
and negative feedback mechanisms (Roser, 1997).  
Oxytocin and gonadotropin releasing hormone (GnRH) are the dominant reproductive 
peptides produced in the hypothalamus, with GnRH being highly conserved across species 
(Senger, 2012). These 2 neuropeptides differ in their hypothalamic origin as well as their 
secretory region. The nanopeptide oxytocin is synthesized by the supraoptic nucleus where the 
axon terminates in the nuerohypophysis, which is also known as the posterior pituitary. As a 
result, oxytocin is secreted directly into the nuerohypophysis and is released into systemic 
circulation (Senger, 2012).  
In contrast, GnRH is synthesized in the medialbasal hypothalamus in males and in both 
the medialbasal hypothalamus and lateral preoptic area in females. The GnRH producing 
neurons contain axons that extend to the stalk region (Rissman et al., 1995). Upon axonal 
stimulation, GnRH is released into the median eminence where it is transported via the 
hypothalamo-hypophyseal portal system to the adenohypophysis (Senger, 2012). This unique 
portal contains small arterial capillaries in the median eminence. Neural GnRH is deposited in 
the primary portal plexus and then transported to a secondary capillary plexus in the 
adenohypophysis, or anterior pituitary (Senger, 2012). The portal system is advantageous for 
hormones with a short half-life and it allows for rapid response from the target tissues. 
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Furthermore, because the neuropeptide is not released directly into systemic circulation, GnRH is 
minimally diluted before reaching the anterior pituitary.  
The hypothalamic structure and source of GnRH differs between males and females. The 
primary sources of hypothalamic GnRH in the female are from the medialbasal hypothalamus 
and lateral preoptic area (Rissman et al., 1995). Females require frequent pulses of GnRH 
released from the lateral preoptic area, which results in greater LH secretion and subsequent 
ovulation of the dominant follicle. In the female fetus, the hypothalamus differentiates with a 
medialbasal hypothalamus and lateral preoptic area as alpha-feto protein binds estradiol (E2) and 
prevents E2 from crossing the blood-brain barrier (Senger, 2012).   
In contrast, the male hypothalamus is defeminized in utero and the medialbasal 
hypothalamus is the sole source of GnRH peptide. During male development, alpha-feto protein 
does not bind to testosterone (T) due to the differing steroid structure. Consequently, T crosses 
the blood-brain barrier and is then converted to E2 via aromatase activity. This E2 exposure in the 
hypothalamus prevents the development of the lateral preoptic area in the male fetus (Senger, 
2012). 
The male reproductive axis is regulated via GnRH binding its cognate receptor on 
gonadotrope cells in the anterior pituitary. Upon formation of the GnRH ligand:receptor 
complex, gonadotrope cells secrete luteinizing hormone (LH) and follicle stimulating hormone 
(FSH). These glycoproteins are trafficked in peripheral circulation from the anterior pituitary to 
the testes (Roser, 1997).  
The testicle participates in the hypothalamo-pituitary-testis axis by producing T, dihydro-
testosterone (DHT), and E2, and it provides negative feedback regulation. Leydig cells in the 
testis express the membrane-bound receptor for LH. Upon LH binding its receptor, Leydig cells 
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produce T. Upon secretion, a portion of T is converted to E2 in Sertoli cells. Testosterone, DHT, 
and E2 are transported in systemic circulation to the hypothalamus where exposure to these 
steroids results in reduced secretion of GnRH, and, consequently, reduced LH and FSH 
production (Roser, 1997). Additionally, FSH binds to Sertoli cells in the testis and induces 
inhibin secretion. Inhibin selectively downregulates FSH secretion from the anterior pituitary 
(Roser, 1997). These negative feedback mechanisms play an important role in regulating 
reproductive hormone levels. 
 
 
 
  
Hypothalamus 
Anterior pituitary 
Testicle 
Sertoli cells 
Leydig cells 
GnRH 
LH 
FSH T 
Inhibin 
E2 
Figure 1.1. Male reproductive axis representing a negative feedback 
regulatory system. Steroid hormones, namely T and E2, produced in the 
testis target the hypothalamus to down regulate GnRH secretion. 
Inhibin, secreted from Sertoli cells, targets gonadotrope cells to 
selectively down regulate FHS secretion. 
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 Equine Seasonality 
Horses are seasonal, long-day polyestrous breeders with the natural breeding season in 
the Northern hemisphere running from early spring through mid-fall. Cyclicity in the mare and 
sperm production in the stallion are regulated by photoperiod, although the effect is more 
pronounced in mares (Grosse et al., 1993). Melatonin is produced in and secreted from the pineal 
gland in greater concentrations during the night, or in the absence of sunlight (Gerlach and 
Aurich, 2000). In the equine, melatonin suppresses the release of GnRH from the hypothalamus 
(Minneman and Wurtman, 1975). As day length increases, melatonin production decreases 
which then allows GnRH to resume pulsatile secretion from the hypothalamus (Argo et al., 
1991). The polyestrous activity of the mare is dependent on elevated levels of GnRH. The surge 
center releases greater concentrations of GnRH, resulting in an LH surge which then leads to 
ovulation of the dominant follicle. However, during short days, elevated melatonin suppresses 
GnRH release and prevents an LH surge. As a result, mares remain anestrus until the days 
become longer.  
Unlike anestrus in the mare, spermatogenesis continues in the stallion year-round (Clay et 
al., 1988). Although melatonin restricts GnRH secretion from the medialbasal hypothalamus 
during short days, sufficient GnRH is produced to regulate and maintain spermatogenesis. The 
increased production of melatonin during the non-breeding season results in decreased 
reproductive hormonal concentrations in stallions and, consequently, reduced sperm production 
(Clay et al., 1988).  
The testes of stallions exposed to short day length year-round still recrudesced and 
spermatogenesis resumed to normal levels during spring and summer (Clay et al., 1988). Basal 
LH concentrations eventually returned to breeding season levels, even though stallions were 
exposed to an inhibitory or non-stimulatory photoperiod (Clay et al., 1988). These authors 
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concluded a separate mechanism may regulate stallion seasonality in conjunction with melatonin 
secretion via the pineal gland.  
The opioid antagonist naloxone can induce an acute LH release from the anterior 
pituitary in stallions during the non-breeding season (Aurich et al., 1994). Following LH-induced 
secretion stimulated by naloxone, T secretion was also found to increase (Gerlach et al., 2002). 
Stallions administered naloxone increased LH concentrations in March, June, and December 
(Gerlach et al., 2002), therefore indicating LH pulsatile secretion and endocrine testicular 
function also may be regulated via opioidergic neural systems (Aurich et al., 1994; Gerlach et al., 
2002). In sheep, there is evidence that dopamine inactivates opioidergic regulation of GnRH 
release during long day length (Tortonese, 1999). In contrast, researchers have not identified an 
interaction between dopaminergic and opioidergic systems in regulating LH release in stallions 
(Gerlach et al., 2002). 
Melatonin not only regulates GnRH release, but also suppresses prolactin secretion 
(Gerlach and Aurich, 2000). In many species, prolactin levels are closely associated with day 
length and fluctuate throughout the year. Because secretion of melatonin is reduced during long 
day length, prolactin is secreted in greater concentration during the equine breeding season 
(Thompson et al., 1987). In conjunction with LH and growth hormone, prolactin assists in 
regulating LH receptors in the testicle and subsequently affects androgen synthesis and 
ultimately spermatogenesis in rats, rams, and boars (Regisford and Katz, 1993; Hondo et al., 
1995; Jedlinska et al., 1995).  
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 GnRH 
 Extra-hypothalamic Expression 
Since the 1970s the hypothalamic decapeptide GnRH has been established as the central 
regulator of the reproductive axis in both males and females (Senger, 2012). As part of the 
hypothalamic-pituitary-gonadal axis, GnRH induces LH and FSH secretion from gonadotrope 
cells in the anterior pituitary upon interaction with its receptor (GnRHR). Even though it is 
commonly accepted that GnRH is localized in the hypothalamus, GnRH has been isolated in 
extra-hypothalamic reproductive and non-reproductive tissues. In reproductive tissues, extra-
hypothalamic mRNA coding GnRH has been identified in seminiferous tubules (Bahk et al., 
1995), seminal plasma (Izumi et al., 1985), germ cells (Paull et al., 1981), the ovary, and 
follicular fluid (Ying et al., 1981; Aten et al., 1987).  
The function of extra-hypothalamic GnRH is poorly understood. Extra-hypothalamic 
GnRH may have several functions aside from gonadotropin secretion, such as regulating 
steroidogenesis (Kang et al., 2003) and cellular proliferation (Gründker and Emons, 2003; Kang 
et al., 2003), or facilitating fertilization (Morales, 1998; Morales et al., 2000). Due to a short 
half-life of approximately 4 min (Eskay et al., 1977; Carone et al., 1984), secretion of GnRH 
from the hypothalamus into the periphery is unlikely. Thus, GnRH has been predicted to be 
synthesized locally in extra-hypothalamic reproductive tissues to exert its biological effect via 
autocrine or paracrine mechanisms (Hsueh and Schaeffer, 1985). 
 GnRH Structure 
The mature GnRH peptide is comprised of 10 AA (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-
Pro-Gly-NH2). Residues between 5 and 8 interact to form a β-II turn (Figure 1.2; Millar, 2005). 
The flexible Gly at residue 6 allows the bent conformation. Agonists and antagonists substitute a 
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D-amino acid in this position to increase half-life, molecule stability, and binding affinity. Both 
the NH2 and COOH termini are necessary for ligand binding; yet, only the NH2 terminus is 
involved in receptor activation. Substitutions in this region, between amino acid (AA) residues 1 
and 3, result in an antagonist molecule (Millar, 2005). 
 
Figure 1.2. Conformation of GnRH upon binding GnRHR. The NH2 and COOH 
termini of GnRH are required to bind GnRHR. However, only NH2 terminus functions 
for receptor activation. Antagonists incorporate a D-amino acid substitution in the 
NH2 region, while agonists substitute a D-amino acid for Gly6. 
Glu 
His 
Trp 
Ser 
Tyr 
Gly 
Leu 
Arg 
Pro 
Gly NH2 terminus 
receptor binding 
and activation 
COOH terminus 
receptor  
binding only 
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 GnRH Receptor 
 Structure 
The receptor for GnRH is a member of the G-protein-coupled-receptor (GPCR) 
superfamily containing 7 transmembrane (TM) domains (Rispoli and Nett, 2005). An 
intracytoplasmic tail is characteristic of most GPCRs (Rispoli and Nett, 2005). However, this 
intracellular domain is absent in GnRHR. It has been suggested the intracytoplasmic tail assists 
in the desensitization and subsequent internalization of GPCRs (Willars et al., 1999), which 
occurs in response to constant ligand binding and continued activation of G proteins (Hislop et 
al., 2001). However, as GnRHR lacks a characteristic cytoplasmic tail, this may indicate an 
evolutionary advantage of GnRHR (Millar, 2005) as the mammalian receptor is internalized at a 
slower rate and is less susceptible to desensitization than other GPCRs (Willars et al., 1999). 
 Cellular Signaling  
Prior to eliciting a cellular response GnRH must first interact with its receptor via a 
hydrophilic pocket within the transmembrane loops. Interaction between GnRH and GnRHR 
leads to the formation of a hormone:receptor complex and results in a conformational change in 
the TM domains of the receptor. Consequently, a cascade of intracellular events, mediated by 
second messengers, follows and activates signal transduction pathways. The GnRHR mediates 
these pathways by coupling to Gq/11 proteins (Naor et al., 1995). Activity from Gq/11 subunits 
leads to an upregulation of phospholipase C (Naor et al., 1995). Phospholipase C cleaves 
phosphatidylinositol 4,5-bisphosphate, a membrane phospholipid, into diacylglycerol and 
inositol triphosphate (Naor et al., 1995). Diacylglycerol remains within the cellular membrane to 
stimulate protein kinase C activity, whereas inositol triphosphate solubilizes in the cytoplasm 
and targets its receptor on smooth endoplasmic reticulum to induce Ca2+ release (Naor et al., 
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1995). An increase in intracellular Ca2+ activates protein kinase C that then phosphorylates and 
activates mitogen-activated protein kinase to increase gene transcription of LH and FSH subunits 
(Naor et al., 1995).  
Gonadotropin releasing hormone regulates different cellular processes by altering the 
pulsatile frequency of its own secretion. With slowed pulse secretion, FSHβ subunit synthesis is 
upregulated (Kaiser et al., 1997). Comparatively, GnRHR and LHβ production are increased 
during increased frequency of GnRH pulsatile secretion (Kaiser et al., 1997). This phenomenon 
has been associated with the increased GnRH secretion prior to the LH surge and greater 
GnRHR numbers on gonadotrope cells prior to ovulation.  
 Extra-pituitary Tissue Expression 
The receptor for GnRH also has been detected in numerous extra-pituitary tissues and 
systems, including the immune system, pancreas, reproductive tumors, and reproductive tissues 
(Walters et al., 2008). Specific reproductive tissues in which GnRHR has been identified consist 
of the uterus (Dong et al., 1998; Choi et al., 2006), ovary (Harwood et al., 1980; Jones et al., 
1980; Reeves et al., 1980; Choi et al., 2006), placenta (Rama and Rao, 2001; Chou et al., 2004), 
spermatozoa (Bull et al., 2000; Lee et al., 2000; Morales et al., 2000), and testes (Ikeda et al., 
1996; Bull et al., 2000) of various mammals.  
Researchers have identified GnRH and GnRHR in the testis of mature rats (Botté et al., 
1998), humans (Bahk et al., 1995), mice (Bull et al., 2000), alpaca (Zerani et al., 2011), sheep 
(Gault et al., 2004), and monkeys (Sharpe and Fraser, 1980). Gonadotropin releasing hormone 
receptor has been detected in interstitial cells (Bahk et al., 1995). Moreover, testicular germ cells 
in mice and rats express GnRHR mRNA (Bull et al., 2000). The nucleotide sequences are 
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identical, confirming that testicular GnRHR is homologous to pituitary GnRHR (Kottler et al., 
1999; Ramakrishnappa et al., 2005).  
In the pituitary, expression of GnRHR is regulated by secretion of its ligand, GnRH. 
Although GnRHR in the testis is identical to the pituitary receptor, the GnRHR regulatory 
system in the testicle is not the same (Ramakrishnappa et al., 2005). In the testes, T upregulates 
GnRHR while LH downregulates the receptor’s expression (Botté et al., 1999; Ramakrishnappa 
et al., 2005). However, LH appears to have no effect on GnRH mRNA levels in the testis of mice 
(Ramakrishnappa et al., 2005). 
 Function of GnRHR in the Testis 
The function of GnRH in the testis appears to be both stimulatory and inhibitory relative 
to peptide concentration. A short-term, low dose of exogenous GnRH results in increased T 
production in adult rat Leydig cells (Sharpe and Cooper, 1982a; Sharpe and Cooper, 1982b). 
Comparatively, a long-term, high dose of GnRH resulted in reduced T production in 
hypophysectomized rats (Ramakrishnappa et al., 2005). The inhibitory function of GnRH 
appears to act by downregulating the GnRHR and intermediary enzymes 3-β-hydroxysteroid 
dehydrogenase and steroidogenic acute regulatory protein (Ramakrishnappa et al., 2005). These 
enzymes are necessary for the conversion of precursor steroids, such as pregnenolone and 
androstenediol, into T. In addition, GnRH has a stimulatory effect on germ cell proliferation, 
where administration of a GnRH agonist stimulated spermatogonial proliferation from damaged 
testes and increased the regeneration of spermatogenesis (Meistrich and Kangasniemi, 1997; 
Matsumiya et al., 1999; Shuttlesworth et al., 2000). 
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 GnRH-II 
 Structure 
Approximately 23 different isoforms of GnRH have been identified (Millar, 2005). Each 
isoform is comprised of 10 AA with at least 50% homology to native GnRH (Dubois et al., 
2002). Because numerous forms of GnRH have been detected, the classical GnRH has now been 
termed GnRH-I. Two isoforms, GnRH-II and GnRH-III, are found in most vertebrates, in 
addition to GnRH-I (Table 1.1; White et al., 1994). However, the only other isoform identified in 
mammals to date is GnRH-II (Sealfon et al., 1997). This novel isoform was originally isolated 
from the chicken hypothalamus (Miyamoto et al., 1984). 
Since its discovery, GnRH-II has been isolated in numerous mammalian species (Millar 
et al., 2001; Wang et al., 2001; Stewart et al., 2009). The AA sequence of GnRH-II (pGlu-His-
Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2) differs from GnRH-I (pGlu-His-Trp-Ser-Tyr-Gly-Leu-
Arg-Pro-Gly-NH2) by substitutions at positions 5, 7, and 8 (Miyamoto et al., 1984). 
Gonadotropin releasing hormone II is highly conserved from boney fish to humans (Temple et 
al., 2003); thus it is thought to be the most ancient form of GnRH (Millar et al., 2004). This 
conservation indicates a prominent selection pressure to retain GnRH-II, as it has been 
maintained over 500 million years of evolution (Millar and King, 1987). 
Although GnRH-I and GnRH-II retain 70% homology (White and Fernald, 1998), the 
stability of the mature decapeptide isoforms differs. It has been well documented that GnRH-I 
has a brief half-life of about 4 min. Gonadotropin releasing hormone II has a similar β 
conformation to GnRH-I, but it appears to require less extensive conformational changes to 
activate its receptor (Pfleger et al., 2002; Millar, 2003). As a result the GnRH-II peptide exhibits 
approximately 6-fold greater stability than GnRH-I (Siler-Khodr and Grayson, 2001). Therefore 
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GnRH-II is less likely to be degraded in systemic circulation. The more stable conformation may 
explain the ubiquitous expression of GnRH-II (Pawson et al., 2003). 
 Neural Synthesis 
Compared to GnRH-II, in mammals GnRH-I is synthesized predominantly in the 
medialbasal hypothalamus where it is trafficked to the anterior pituitary via the hypthalamo-
hypophyseal portal system to interact with GnRHR-I expressed on gonadotrope cells. By 
contrast, the majority of neural GnRH-II originates from the midbrain. In the musk shrew, 
GnRH-II has been found in the hindbrain, medial habenula, midbrain central grey, 
hypothalamus, and medial septum (Rissman et al., 1995). However, the majority of GnRH-II 
synthesis takes place in the periphery in a wide range of tissues such as the kidney, bone, 
prostate, placenta, breast, endometrium, ovary, and testis (Millar, 2003). 
 
 
 
Table 1.1. The AA sequences of GnRH isoforms detected in vertebrates 
Isoform Amino Acid Sequence1 
GnRH-I pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 
GnRH-II pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2 
GnRH-III pGly-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2 
                                                
1Amino acid residues in bold differ from the native mammalian GnRH-I 
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 Role in Behavior 
In mammalian neural tissue, GnRH-II regulates several different physiological functions 
(Gründker et al., 2002; Temple et al., 2003; Kauffman and Rissman, 2004; Kauffman et al., 
2005). For instance, GnRH-II in the female musk shrew plays a modulatory role between energy 
status and reproductive behavior (Temple et al., 2003). Restriction fed females showed reduced 
sexual receptivity (Temple et al., 2003). However, when dosed with GnRH-II, the inhibitory 
effect of food restriction was reversed and the females exhibited increased mating behavior 
(Temple et al., 2003). Conversely, female musk shrews that were fed ad libitum did not show a 
stimulatory effect when injected with GnRH-II (Schiml and Rissman, 2000). Temple et al. 
(2003) suggested that under ad libitum feeding conditions GnRH-II is released at basal levels, 
and at this concentration, females are receptive to mating. Limit-fed females released GnRH-II at 
a reduced rate and exhibited minimal reproductive behavior (Temple et al., 2003). This effect of 
GnRH-II regulating female reproductive behavior has also be confirmed in ring doves (King and 
Millar, 1979) and song sparrows (Maney et al., 1997). Therefore, neural GnRH-II appears to 
signal the energetic state in females of some species. If dietary energy is sufficient, GnRH-II is 
likely to act as a permissive factor that allows mating behavior (Kauffman and Rissman, 2004). 
 Role in Nutrition 
In addition to regulating mating behavior, GnRH-II also appears to play a role in 
regulating food intake. When in a negative energy state, GnRH-II is released at minimal levels 
and stimulates increased feed intake (Kauffman and Rissman, 2004). Alternatively, excessive 
food intake leads to greater GnRH-II secretion, which signals the brain to reduce food 
consumption to basal levels (Kauffman and Rissman, 2004). An infusion of GnRH-II in ad 
libitum and restriction fed musk shrews resulted in reduced feed intake (Kauffman and Rissman, 
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2004). However, the inhibitory effect of GnRH-II on food intake persisted only a few hours 
(Kauffman and Rissman, 2004). 
 GnRHR-II 
 Structure 
Like GnRH-I, GnRH-II binds a specific receptor (GnRHR-II). Gonadotropin releasing 
hormone receptor II was originally isolated from the African catfish and is a member of the 
GPCR superfamily containing 7 TM domains (Tensen et al., 1997). There is only 40% homology 
between GnRHR-II and GnRHR-I (Figure 1.3; Kauffman and Rissman, 2004). A significant 
difference between the receptors is the retention of an intracytoplasmic tail on GnRHR-II (379 
AA) that is absent on GnRHR-I (328 AA). This intracellular domain assists in the desensitization 
and internalization of GPCR receptors (Willars et al., 1999) and indicates more rapid 
internalization and desensitization of GnRHR-II compared to GnRHR-I (Heding et al., 1998).  
 Tissue Expression 
Similarly to GnRH-II, GnRHR-II is ubiquitously expressed across tissue types (Millar et 
al., 2001). In the human and marmoset, GnRHR-II mRNA has been detected in numerous cell 
types, such as neural tissue, cardiac muscle, digestive organs, respiratory tissue, immune system, 
reproductive tissues and reproductive tumors (Neill et al., 2001). Like GnRH-II, it appears 
GnRHR-II expression is greatest in extra-pituitary tissues (Millar et al., 2001). Expression of 
GnRHR-II is particularly elevated in marmoset reproductive tissues (Millar et al., 2001).  
Both the ligand and receptor of GnRH-II have been characterized in the boar testis and it 
appears the GnRH-II system plays an important role in spermatogenesis (Bowen et al., 2006; 
Desaulniers et al., 2015). Immunization against GnRH-II in the boar results in reduced T 
production, but does not affect LH secretion (Bowen et al., 2006). Dosing the same immunized 
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boars with LH does not increase Leydig cell secretion of T (Bowen et al., 2006). Furthermore, 
GnRH-II has also been found to increase T production independent of LH secretion (Desaulniers 
et al., 2015). In the testis, GnRHR-II has been identified in interstitial cells, primarily Leydig 
cells, as well as seminiferous tubules (Desaulniers et al., 2015).  
 
 
Figure 1.3. A graphical comparison of the monkey GnRHR-II and human GnRHR-I. The 
most notable difference is the retention of an intracytoplasmic tail in GnRHR-II. Figure 
from Neil (2002). 
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 Ligand and Receptor Isoform Interaction 
 Ligand:Receptor Complex 
The ligand:receptor complex is formed by the interaction of specific residues in the 
ligand and receptor. This interaction leads to receptor activation and subsequent signal 
transduction. The Arg8 residue of GnRH-I is critical for high affinity binding to GnRHR-I 
(Millar et al., 2004). Gonadotropin releasing hormone II also binds GnRHR-I, however, with 
much lower affinity as GnRH-II substitutes Tyr8 for Arg8. Conserved residues found in both 
ligand isoforms, His2 and Trp3, are necessary for activation of GnRHR-I (Sealfon et al., 1997). 
Comparatively, Trp7 and Tyr8 are essential for binding and activation of GnRHR-II (Wang et al., 
2003).  
Particular receptor residues are also important for ligand recognition. Specific regions 
that differ between GnRHR-I and GnRHR-II increase ligand selectivity (Li et al., 2005). For 
GnRHR-II, extracellular loop 3 and extracellular loop 3 proximal TM 7 are responsible for high 
affinity binding of GnRH-II to its receptor (Li et al., 2005; Mamputha et al., 2007). Residues 
Asp97, Asn101, and Lys120 are conserved in GnRHR-I and GnRHR-II, and are important for 
recognition of both ligand isoforms (Zhou et al., 1995; Davidson et al., 1996; Flanagan et al., 
2000; Mamputha et al., 2007). Although conserved between GnRHR-I and GnRHR-II, there are 
subtle differences these residues play upon forming the GnRH-I:GnRHR-I or GnRH-II:GnRHR-
II complex (Mamputha et al., 2007). 
 Cross Ligand Interaction 
In addition to binding its cognate receptor, GnRH-II is also capable of interacting with 
the GnRHR-I binding pocket. Similarly, GnRH-I is capable of binding GnRHR-II, however with 
100-fold reduced affinity compared to GnRH-II (Millar, 2003). Little is known of the effects 
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GnRH-I elicits upon binding GnRHR-II, but it appears GnRH-I antagonists have the ability to 
act as agonists when interacting with the GnRHR-II binding pocket (Millar et al., 2001).  
Gonadotropin releasing hormone-II is capable of binding GnRHR-I in the anterior 
pituitary and mediating gonadotropin release (Gründker et al., 2002). However, the second 
ligand has a 10-fold lower affinity binding to GnRHR-I, making GnRH-II a weak stimulator of 
gonadotropin release and only 10% as effective in stimulating ovulation as GnRH-I (Gründker et 
al., 2002; Neill, 2002). Other potential functions of GnRH-II mediated via GnRHR-I include 
regulation of female reproductive behavior (Kauffman et al., 2005) and feed intake (Kauffman 
and Rissman, 2004). Furthermore, GnRH-II has shown anti-prolific effects on cancerous tissues 
that may be mediated through GnRHR-I or GnRHR-II (Gründker et al., 2002). 
 Disruptive Genetic Mutations 
Several species code for disruptive genetic mutations in the GnRHR-II gene. In the 
mouse there is an absence of both GnRH-II ligand and receptor genes in the genome, while the 
rat genome retains a fragment of the GnRH-II gene. Of the 22 mammalian species examined by 
Stewart et al. (2009), 10 species retained genetic coding to produce prepro-GnRH-II, whereas 
only 8 species maintained the ability to produce a full-length functional GnRHR-II. Few species, 
including the macaque, marmoset, tree shrew, and pig, retain functional encoding genes to 
produce both GnRH-II and GnRHR-II transcripts (Stewart et al., 2009). 
Humans maintain the ability to secrete the GnRH-II hormone; however, the human 
GnRHR-II gene has a premature stop codon in exon 2 (Morgan et al., 2003). This exon encodes 
the extracellular region of loop 2. Another start codon downstream initiates the transcription of a 
gene fragment, which has been termed GnRHR-II-reliquum (Pawson et al., 2003). The protein 
translation of this gene fragment is thought to inhibit GnRHR-I function in the anterior pituitary 
  
18 
(Pawson et al., 2003). Like humans, horses also retain the gene encoding prepro-GnRH-II 
(Stewart et al., 2009). The horse also possesses a mutated GnRHR-II gene with frameshifts in 
exon 2 and a premature stop codon in exon 3 (Stewart et al., 2009). However, compared to the 
human, the horse may transcribe a larger portion of GnRHR-II as the position of the premature 
stop codon in the equine is much closer to the 3’ end (Stewart et al., 2009).  
While it appears the GnRHR-II gene is transcriptionally active in the sheep, it encodes a 
premature stop codon in exon 1 (Gault et al., 2004). Furthermore, sheep also have a 51 base pair 
deletion in exon 2 (Gault et al., 2004). Therefore it is unlikely sheep are able to produce a 
functional GnRH-II receptor (Gault et al., 2004). Sheep also differ from the horse and human as 
they are not predicted to be able to synthesize the GnRH-II peptide (Gault et al., 2004; Stewart et 
al., 2009). 
Investigation of numerous mammalian genomes indicates retention of a majority of the 
GnRH-II hormone and receptor gene (Stewart et al., 2009). Even though it appears several 
species have coding errors in either the hormone or receptor gene, ancestral mammalian species 
may have required the GnRH-II system for survival (Stewart et al., 2009). However, during 
evolution, this system appears to have become non-essential to the survival of mammalian 
species that now have coding errors (Stewart et al., 2009). Indeed, it has been proposed GnRHR-
I may have replaced GnRHR-II in the evolution of certain species (Millar, 2003). Yet, the 
GnRH-II system must still be functionally relevant to those species, such as the pig, tree shrew, 
macaque, and marmoset, that retain the GnRH-II hormone and receptor gene (Stewart et al., 
2009). 
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 Role in Cancer 
In recent decades, agonists and antagonists of mammalian GnRH isoforms have been 
used as therapeutic agents in the treatment of reproductive tumors (Cheung and Wong, 2008). 
The effectiveness of these therapies is predominantly attributed to the presence of GnRHR-I in 
reproductive cancerous tumors (Neill et al., 2001; Cheung and Wong, 2008). Gonadotropin 
releasing hormone receptor-I has been detected in breast, endometrial, ovarian, and prostate 
tumors, which are dependent on sex steroids (Limonta et al., 2001). In cancerous cells GnRHR-I 
couples Gαi rather than coupling to Gq/11 in the anterior pituitary (Imai et al., 1997). Coupling to 
Gαi results in a separate signaling cascade in tumor cells that is involved in cellular growth, 
metastasis, and survival (Cheung and Wong, 2008).  
As with T secretion in the testis, GnRH-I is able to regulate cancerous cellular growth in 
a biphasic manner (Arencibia and Schally, 2000; Cheung et al., 2006; Chen et al., 2007). At a 
low dose, GnRH-I agonists promote cellular growth, whereas administration of a greater 
concentration of GnRH-I agonists inhibits cellular proliferation (Arencibia and Schally, 2000; 
Cheung et al., 2006). However, it appears GnRH-I antagonists more effectively inhibit cellular 
growth compared to GnRH-I agonists (Yano et al., 1994). It has been proposed that antagonists 
limit cancerous cellular proliferation by reducing gonadotropin release and subsequently 
decreasing sex-steroid production (Schally, 1999; Cheung and Wong, 2008).  
Compared to GnRH-I, GnRH-II has even more potent anti-prolific effects on 
reproductive cancers. When dosed at similar levels, GnRH-II inhibits cellular growth more than 
GnRH-I (Gründker et al., 2002). There is contradicting evidence, however, as to whether GnRH-
II acts via GnRHR-I or GnRHR-II in suppressing tumor growth. In cancer cell lines that express 
GnRHR-II mRNA and lack GnRHR-I mRNA, GnRH-II inhibits cellular proliferation, whereas 
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GnRH-I had no effect (Gründker et al., 2002). However, it is still unclear if the human is capable 
of producing a functional GnRHR-II (Neill, 2002; Millar, 2005).  
 Autocrine and Paracrine Cellular Signaling 
Primary hormonal regulation of male reproduction has been attributed to the 
hypothalamo-pituitary-testes axis. In addition to negative feedback regulation of stallion 
reproduction, autocrine and paracrine systems regulate steroidogenesis and spermatogenesis 
locally within the testis (Figure 1.4; Roser, 2008). Autocrine mechanisms function by acting on 
the same cellular type; conversely, paracrine signaling molecules are produced by a cellular type 
and act on a neighboring cellular type (Heindel and Treinen, 1989). The autocrine and paracrine 
regulatory functions in the equine testis have been minimally investigated and these systems are 
poorly understood (Roser, 2008). Hormones that have been investigated in the stallion testis are 
androgens, estrogens, inhibin, activin, insulin-like growth factor-1 (IGF-1), transferrin, insulin-
like peptide-3, β-endorphins, and oxytocin (Roser, 2008). 
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Figure 1.4. Diagram of potential local interactions in the equine testis including 
gonadotropin releasing hormone (GnRH), insulin-like growth factor 1 (IGF-1), insulin like 
peptide 3 (INSL3), inhibin (INH), activin (ACT), beta endorphin (β-EP), transferrin (Trans), 
basic fibroblast growth factor (bFGF), transforming growth factor (TGF), transforming 
growth factor beta (TGF-β), transforming growth factor alpha (TGF-α), interleukin-1 (IL-1), 
sulphated glycoprotein (SGP), nerve growth factor (NGF), peritubular modifying substance 
(PmodS), oxytocin (OT), vasopressin (VP), testosterone (T), estradiol (E2).  Highlighted 
factors have been confirmed in the stallion. Normal testicular function depends on intricate 
autocrine and paracrine hormone regulation of steroidogenesis and spermatogenesis. Figure 
from Roser (2008).  
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 Androgens 
The testicular environment has a 100 to 500 fold greater concentration of T than systemic 
blood. This is the result of androgen binding protein (ABP), produced by Sertoli cells, 
sequestering T, produced by Leydig cells, and retaining it in the testicle (Dohle et al., 2003). 
Testosterone can be converted to E2 and it induces several paracrine and autocrine effects within 
testicular tissue.  
Pearl et al. (2011) investigated testicular expression of the androgen receptor (AR) in pre-
pubertal, peri-pubertal, and post-pubertal stallions. Immunohistochemistry revealed the AR was 
expressed in the nucleus of Leydig, Sertoli, and peritubular myoid cells (Pearl et al., 2011). 
There were no differences in expression of AR among the different age groups analyzed. There 
was also no evidence of AR expression in germ cells (Pearl et al., 2011; Smith and Walker, 
2014). Expression of AR on Sertoli cells is greatest during the transition stage of tight junction 
regeneration (Bremner et al., 1994; Zhou et al., 2002). This indicates androgens may be involved 
in the formation of new tight junctions and the progression of spermatogongia into meiosis in the 
adluminal section of seminiferous tubules (Meng et al., 2005). 
Further actions of T within the testis include an autocrine effect on Leydig cells (Xu et 
al., 2007). Removal of AR from Leydig cells via genetic knockout resulted in a disruption of 
spermatogenesis and a reduction in T production (Xu et al., 2007). Additionally, Sertoli cell AR 
knockout mice also experienced a disruption of spermatogenesis (Holdcraft and Braun, 2004). 
Male mice with the AR knockout gene in Sertoli cells showed a reduction in spermeiogenesis, 
particularly in the differentiation and elongation of spermatids (Holdcraft and Braun, 2004).  
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 Estrogens 
Estrogens are historically recognized for their biological significance in the regulation of 
female reproduction. However, in the last decade researchers have also examined the biological 
activity of estrogens in male reproduction and spermatogenesis. The final enzyme in the 
steriodegenic pathway, aromatase, converts T to E2 and is the focus for scientists who quantify 
estrogen production. Aromatase is expressed in all testicular cells except peritubular myoid cells 
(Silandre et al., 2007; Bois et al., 2010; Carreau et al., 2011). 
Sertoli cells are the main source of estrogen produced in the immature male (Hess and 
Roser, 2004; Roser, 2008). As maturity is achieved in the rat, Leydig cells increase aromatase 
activity 3 to 4 fold (Roser, 2008). Parlevliet et al. (2006) reported E2 concentrations were greater 
in adult stallions when compared to pre-pubertal stallions. This is likely the result of greater T 
production in the post-pubertal animals as T is a precursor steroid of estrogens and increased 
aromatase activity (Senger, 2012).  
Carreau et al. (2003) revealed approximately 60% of aromatase activity originates from 
germ cells. Furthermore, the concentration of aromatase varies at differing stages of sperm cell 
development. Spermatocytes express a greater amount of aromatase transcript compared to 
haploid spermatids and spermatozoa (Carreau et al., 2011). Aromatase and E2 have been 
identified in ejaculated spermatozoa (Carreau et al., 2010). It appears human ejaculated 
spermatozoa have the ability to convert androgens to estrogens via aromatase (Lambard and 
Carreau, 2005). Compared to motile sperm after purification, immotile sperm show 28% 
decreased expression of aromatase (Carreau et al., 2010). 
Estrogens play a role in regulating testicular function (Hess and Roser, 2004), 
spermatogenesis (Ebling et al., 2000), acrosome formation (Luconi et al., 1999), and fertilization 
(Fraser et al., 2006). Aromatase knockout mice were developed to investigate estrogen’s role in 
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the testis. Presumably as a result of the aromatase knockout, these mice had abnormal acrosome 
development (Luconi et al., 1999). Fraser et al. (2006) concluded that in the presence of estradiol 
and phytoestrogens, sperm capacitation, acrosome reaction, and fertilizing capacity were 
increased.  
Estrogens can bind to 2 different receptors, estrogen receptor alpha (ERα) or estrogen 
receptor beta (ERβ; Kuiper et al., 1997; Pearl et al., 2011). The expression of either receptor is 
dependent on the cellular type and animal age (Hess and Roser, 2004). In the stallion testis, ERα 
expression varies between pre-pubertal, peri-pubertal, and post-pubertal males (Pearl et al., 
2011). In the pre-pubertal and peri-pubertal stallions, expression was identified in the nucleus of 
Sertoli, Leydig, and germ cells. In the mature testis ERα was restricted to most Leydig, germ, 
and peritubular myoid cells (Pearl et al., 2011). Pre-pubertal stallions expressed ERβ in germ 
cells (Pearl et al., 2011). Regardless of age, ERβ was localized to Leydig and Sertoli cell 
cytoplasm as well as Sertoli cell nuclei in the equine (Pearl et al., 2011). 
 Inhibins 
The glycoprotein inhibin is a member of the transforming growth factor-β (TGF-β) super 
family (Chang et al., 2002). The dimeric nature of inhibin is formed by an α and β subunit. Two 
forms of inhibin are present in most male species. Inhibin A consists of an α and βA subunit, 
whereas inhibin B is composed of an α and βB subunit (Phillips, 2005). In most male species 
inhibin B is the dominant form secreted, except the ram which primarily produces inhibin A 
(McNeilly et al., 2002).  
The testicle is the prominent source of inhibin in the male as castration results in a rapid 
decline of circulating inhibin levels (Ishida et al., 1990). The α subunit of inhibin is produced in 
Leydig cells, but it most commonly originates in Sertoli cells (Bicsak et al., 1987; Risbridger et 
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al., 1989). The βA subunit is expressed in Sertoli and peritubular cells (Buzzard et al., 2004). The 
βB subunit mRNA is expressed Sertoli cells and germ cells, including spermatogonia, primary 
spermatocytes, and round spermatids (Buzzard et al., 2004; de Kretser et al., 2004).  
Contrary to other hormones that interact with a specific receptor, inhibin requires a co-
receptor and has the ability to interact with the activin receptor (Lewis et al., 2000; Hedger and 
Winnall, 2012). The primary function of inhibin is to inhibit FSH secretion from the anterior 
pituitary via classical negative feedback (Bilezikjian et al., 2004). This glycoprotein acts to 
suppress FSH production through competitive binding of the activin receptor, effectively 
blocking activin from exerting its biological effect of upregulating FSH secretion (Bilezikjian et 
al., 2004).  
Circulating concentrations of inhibin B have been associated positively with Sertoli cell 
numbers and concentration of sperm (O'Connor and De Kretser, 2004). Thus, inhibin has been 
proposed as a potential fertility marker in the male (O'Connor and De Kretser, 2004). However, 
immunization against inhibin has also been hypothesized to increase fertility due to greater FSH 
secretion (Phillips, 2005).  
Aside from the endocrine role inhibin plays by regulating FSH production, little is 
understood pertaining to other paracrine and autrocrine factors in the testis (Suresh et al., 2011). 
In one in vitro study, inhibins appeared to regulate human Leydig and Sertoli cell proliferation, 
differentiation, and steroidogenesis (Meachem et al., 2001). Yet, these regulatory functions of 
inhibin have not been demostrated in vivo (Suresh et al., 2011).  
 Activins 
Activins are structurally similar to inhibins and belong to the same super family, TGF-
b (Chang et al., 2002). Activins are comprised of β dimers (Phillips and Woodruff, 2004), activin 
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A (βA - β A), activin B (βB - βB), and heterodimer activin AB (βA - βB). Activin A is the 
glycoprotein that has been most thoroughly studied (Phillips and Woodruff, 2004). In the testis, 
activin A is secreted largely from Sertoli (de Winter et al., 1993), peritubular (de Winter et al., 
1994) and interstitial cells (Lee et al., 1989), which produce the βA subunit. The testis was 
identified as the sole source of inhibin; however, activin levels post-castration remain unchanged 
(de Kretser et al., 2004). Therefore activin appears to originate from other sources, in addition to 
testicular tissue (de Kretser et al., 2004). Activins induce their biological effect by interacting 
with 1 of 2 membrane-bound receptors that are specific to the activin (Hedger and Winnall, 
2012). 
Activin is able to influence various biological functions in the periphery, including 
inflammation (de Kretser et al., 2004) and the immune response (Phillips, 2005; Hedger and 
Winnall, 2012). Paracrine and autocrine functions of activin in the testis have also been 
investigated. Steriodogenesis was decreased in cultured porcine Leydig cells in the presence of 
activin (Hedger et al., 2011). Additionally, T secretion from Leydig cells was inhibited by activin 
(Hsueh et al., 1987; Lin et al., 1989). 
 Insulin-like Growth Factor-1 
Insulin-like growth factor-1 and the insulin-like growth factor-1 receptor (IGF-1R) have 
been localized in the equine testis (Yoon et al., 2011). Utilizing immunohistochemistry, IGF-1 
was observed in Leydig cell cytoplasm and spermatogonia with expression increasing from pre-
pubertal to post-pubertal stallions, then decreasing to moderate expression in adult and aged 
stallions (Yoon et al., 2011). Additionally, IGF-1R was observed in Leydig cells and 
spermatogonia and followed an age dependent pattern. Expression of IGF-1R was most intense 
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in Leydig cells from post-pubertal, adult, and aged stallions (Yoon et al., 2011). Expression of 
IGF-1 and IGF-1R was not observed in Sertoli cells at any age (Yoon et al., 2011).  
The restriction of IGF-1 and its cognate receptor to Leydig cells and spermatogonia is 
indicative of a paracrine or autocrine relationship (Yoon et al., 2011). In vitro culturing of 
stallion Leydig cells with IGF-1 reduced the percentage of apoptotic cells (Yoon and Roser, 
2010). Additional effects of IGF-1 in the testis include regulation of Leydig cell populations and 
spermatogonial differentiation (Tajima et al., 1995; Yoon and Roser, 2010), increased T 
production from Leydig cells (Lin et al., 1996), and regulation of DNA synthesis from 
spermatogonial cells (Söder et al., 1992).   
 Conclusion 
While the regulatory functions of the hypothalamic-pituitary-testis axis have been 
characterized in the stallion, the interactions within the testis that promote steroidogenesis and 
spermatogenesis are poorly understood. Additionally, GnRH-I has been localized to numerous 
tissue types of multiple mammals. However, research investigating the localization of this 
peptide has been limited in the horse. And although, GnRH-II has been isolated in the equine 
genome, the transcription and/or translation of this gene have not been evaluated in the horse. 
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Chapter 2 - Identification of GnRH Isoforms and their Cognate 
Receptors in the Equine Testis 
 Introduction 
The interaction between the hypothalamic decapeptide gonadotropin-releasing hormone 
(GnRH) and its cognate receptor (GnRHR) on gonadotropes of the anterior pituitary gland has 
been established as a central regulator of reproduction. The GnRH complex is typically 
associated with anterior pituitary function, as GnRH secreted from hypothalamic neurons targets 
its receptor in the anterior pituitary. Even so, researchers have identified GnRH and GnRHR in 
peripheral reproductive tissues such as the uterus (Dong et al., 1998; Choi et al., 2006), ovary 
(Harwood et al., 1980; Jones et al., 1980; Reeves et al., 1980; Choi et al., 2006), placenta (Rama 
and Rao, 2001; Chou et al., 2004), spermatozoa (Bull et al., 2000; Lee et al., 2000; Morales et 
al., 2000), and testes (Ikeda et al., 1996; Bull et al., 2000) of numerous mammals. 
Approximately 23 isoforms of GnRH have been identified (Millar, 2005). As a result, the 
classical GnRH has now been termed GnRH-I to distinguish it from other isoforms. Only 1 other 
isoform has been identified in mammals: GnRH-II, which was originally isolated from the 
chicken hypothalamus (Miyamoto et al., 1984). The amino acid (AA) sequence of GnRH-II 
differs from GnRH-I by substitutions at positions 5, 7, and 8. Moreover, GnRH-II is highly 
conserved from boney fish to humans (Temple et al., 2003), thus it has been suggested to be the 
most ancient form of GnRH. There appears to be prominent selection pressure to retain GnRH-II, 
as it has been maintained over 500 million yr of evolution (Millar and King, 1987). 
Similar to GnRH-I, GnRH-II binds a specific receptor (GnRHR-II). Originally isolated in 
the African catfish (Tensen et al., 1997), GnRHR-II is also a member of the G-protein-coupled-
receptor (GPCR) superfamily and contains 7 transmembrane (TM) domains. Most GPCRs, 
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including GnRHR-II, have an intracytoplasmic tail; however, this intracellular domain is absent 
in GnRHR-I. The GnRHR-II gene has been detected in numerous non-mammalian vertebrates 
(Troskie et al., 1997) and several mammalian species, including the human, horse, and pig  
(Stewart et al., 2009). However, coding errors in the GnRHR-II gene of some species prevent the 
production of a functional receptor (Stewart et al., 2009).  
In addition to binding its cognate receptor, GnRH-II also is capable of interacting with 
the GnRHR-I binding pocket. In the anterior pituitary, GnRH-II can bind GnRHR-I and mediate 
gonadotropin release (Densmore and Urbanski, 2003; Okada et al., 2003). However, GnRH-II is 
only 10% as effective at stimulating ovulation as GnRH-I (Gründker et al., 2002). Other 
potential functions of GnRH-II that are mediated by binding to GnRHR-I include regulation of 
female reproductive behavior (Kauffman et al., 2005) and feed intake (Kauffman and Rissman, 
2004). Furthermore, GnRH-II has anti-proliferative effects on cancerous tissues that may be 
mediated through GnRHR-I or GnRHR-II (Gründker et al., 2002).  
In the testis, GnRH-I and GnRH-II appear to affect testosterone secretion. Immunization 
against GnRH-II in the boar resulted in reduced testosterone production compared to control 
boars, without affecting LH secretion (Bowen et al., 2006). Indeed, GnRHR-II has been localized 
in the boar testis and it appears GnRH-II is able to stimulate testosterone secretion independent 
of LH (Desaulniers et al., 2015). Researchers also have suggested GnRH-I stimulates 
testosterone production in mouse and rat testes (Ikeda et al., 1996; Bull et al., 2000). 
 Locally produced GnRH-I and GnRH-II in the mammalian testis may play an important 
role in steroidogenesis. Therefore the objective of this study was to examine gene expression and 
protein production of GnRH-I, GnRH-II and their cognate receptors in the equine testis and to 
identify differences between pre-pubertal and mature stallions. 
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 Materials and Methods 
 Tissue Collection 
Testicular tissue was collected from 15 stallions ranging in age from 7 mo to 15 yr during 
routine castrations at the Kansas State University Veterinary Health Center (Manhattan, KS). 
Stallions were segregated by age (colts < 2 yr, n = 5; or stallions ≥ 2 yr, n = 10). Tissue samples 
were processed immediately following castration. BioProduct’s RNase AWAYTM surface 
decontaminant (Fisher Scientific, Pittsburgh, PA) was used to maintain an RNase-free area while 
processing tissue samples for mRNA analysis. RNase-free forceps and razor blades were used to 
harvest approximately 100 mg of tissue from the testicular parenchyma and samples were 
submerged in 1 mL of RNAlater (Life Technologies, Grand Island, NY), incubated at 4°C 
overnight, and moved to a -20°C freezer until further processing. In addition, approximately 400 
mg of testicular tissue from each stallion also was transferred into a microcentrifuge tube, flash 
frozen in liquid nitrogen, and stored at -80°C for later protein analysis.  
 RT-PCR Analysis 
 RNA Extraction 
Testicular tissue was removed from RNAlater and placed in 1 mL of TRIzol® Reagent 
(Life Technologies, Grand Island, NY) on ice. Tissue was homogenized using a Biospec Tissue 
Tearor (Bartlesville, OK) that had been soaked in 3% H2O2 to inactivate RNases. Samples were 
vortexed with 200 µL chloroform and centrifuged at 14,000 x g for 15 min at 4°C. The aqueous 
layer was transferred to a microcentrifuge tube with 500 µL of isopropyl alcohol. Samples were 
centrifuged at 12,000 x g for 10 min at 4°C to pellet RNA. Supernatant was removed and the 
pellet was rinsed with 70% ethanol and stored at -80°C. After brief centrifugation, ethanol was 
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removed and the pellet was allowed to air dry. The pellet was resuspended in 50 µL of nuclease 
free water with 0.5 µL of RNase OUT (Invitrogen, Grand Island, NY).  
To remove any genomic DNA contamination, samples were incubated with 1 µL 10X 
RQ1 buffer, 4 µL RQ1 DNase and 0.5 µL RNase OUT for 30 min at 37°C in a MJ Research 
thermocycler (Hercules, CA). Finally, 1 µL of stop buffer was added to each sample, which was 
then incubated at 65°C for 10 min.  
 Reverse Transcription  
Following removal of any DNA, total RNA was converted to cDNA. After quantifying 
total RNA using a Nanodrop spectrophotometer (ThermoFisher, Pittsburg, PA), 2 µg of RNA 
were diluted to a volume of 15.15 µL with nuclease free water. Then, 2 µL of 10 mM random 
primers (Invitrogen) or an oligo dT primer (Promega, Madison, WI) were added. Samples were 
incubated at 37°C for 5 min. Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV 
RT) was used to convert RNA to cDNA. The reverse transcription reaction was completed with 
5.0 µL 5X M-MLV RT buffer, 1.25 µL 10 µM dNTP, 0.6 µL RNase out, and 1.0 µL M-MLV 
RT by incubation at 37°C for 1 h and 70°C for 15 min. The resulting cDNA was stored at -20°C. 
To verify there was no genomic DNA contamination, a second control reaction that lacked 
reverse transcriptase was performed on each sample and was designated the no-RT control. 
 Conventional PCR 
Next, samples were subjected to conventional PCR analysis by following Promega’s Taq 
Polymerase protocol. First, detection of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
cDNA was performed to confirm a successful RT reaction had occurred and to verify the 
absence of genomic DNA. Gene specific primers for equine GnRH-I, GnRHR-I, GnRH-II, and 
GnRHR-II were purchased from Integrated DNA Technologies (Table 1). Each PCR began with 
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2 min at 95°C. Next, there were 40 cycles of 30 sec at 95°C (melting), 30 sec at the appropriate 
annealing temperature for each primer pair and gene, and 60 sec at 72°C (extension). The 
annealing temperature for GnRH-II, GnRHR-II, and GnRHR-I was 55°C and was 56°C for 
GnRH-I. After 40 cycles, the thermocycler remained at 72°C for 10 min for final extension.  
After completion of the PCR, each product was run on a 1% agarose gel via gel 
electrophoresis in sodium borate running buffer and imaged under an ultraviolet light. A 
representative PCR product for each gene was column purified using a Gel/PCR DNA 
Fragments Extraction Kit (IBI Scientific, Kapp Court Peosta, IA) and sequenced at the 
University of Nebraska Medical Center (Omaha, NE) to confirm product identity. The online 
translation tool ExPASy (Bioinformatics Research Portal) was used to predict the AA sequence 
of sequenced transcripts.  
Primers initially used for GnRHR-II targeted a small region of the gene in exons 1 and 2. 
Sequencing confirmed the product identity as equine GnRHR-II. For further characterization, 
multiple gene specific primers were purchased from Integrated DNA Technologies. Forward 
primers targeted the 5’ end of exon 1 and exon 2 and reverse primers targeted the 3’ end of exon 
3. Additionally, due to low abundance of transcript, a second round of PCR was completed using 
a nested primer pair to amplify a greater volume of product. 
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Table 2.1. Gene specific primers utilized to target equine GnRH-I and GnRH-II ligand and 
receptor cDNA 
Gene Sequence Name Primer Sequence 
GnRH-I hGnRH1F79 5’-AGCCAACACTGGTCCTATGG-3’ 
 hGnRH1R269 5’-TCCTCTTCAATCAGGCTTTC-3’ 
 hGnRH1R278 5’-TGCCAAGTTTCCTCTTCAAT-3’ 
GnRHR-I hGnRHR1F436 5’-CCCCAGCCTTCATGATGGTA-3’ 
 hGnRHR1F453 5’-GTAGTGATCAGCCTGGACCG-3’ 
 hGnRHR1R633 5’-AACCTTCTGTCTGTCCGGAG-3’ 
GnRH-II hGnRH2F2021 5’-CACTGGTCACATGGCTGGTA-3’ 
 hGnRH2R2230 5’-CTGTACCAGTGTCTGCTTCC-3’ 
 hGnRH2F2055 5’-GAGCCTCTAGTTCACCCCAG-3’ 
 hGnRH2R2257 5’-GCCTGTCACCCTACTTACCA-3’ 
GnRHR-II hGnRHR2F116 5’-AGGTCCGAGTGGGAGTGAC-3’ 
 hGnRHR2F151 5’-TCTTCTGCTGGTGGGAACTT-3’ 
 hGnRHR2F232 5’-CGACTCTTTGCCCATTTAGC-3’ 
 hGnRHR2F251 5’-CAGCTGCCGACTTACTGGT-3’ 
 hGnRHR2F515 5’-TGTTCCTGTTCCATACTGTCCG-3’ 
 hGnRHR2F545 5’-GCCCAGTCTCCTTCACTCAA-3’ 
 hGnRHR2F564 5’-ATGTATCACCAAAGGCAGCT-3’ 
 hGnRHR2R617 5’-AGGTTATAGGTGGTCTCTTG-3’ 
 hGnRHR2R638 5’-AAGGCAGCAGAAGGTGAGAA-3’ 
 hGnRHR2R1086 5’-TTTGTTTGTACTTGCAGCTGTCT-3’ 
 hGnRHR2R1105 5’-TGCCCTTCTTCCTGCCACAT-3’ 
 hGnRHR2R1123 5’-CGTCTCTTTTGTTTCTCCTGCC-3’ 
 hGnRHR2R1159 5’-GTATACTCTGTTGTGAGCAAATGG-3’ 
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 Antibody Validation 
To detect GnRHR-I protein, a goat polyclonal antibody directed against GnRHR-I (sc-
8681; Santa Cruz Biotechnology; Santa Cruz, CA) was utilized. The epitope for this peptide was 
mapped against the c-terminus of the human GnRHR-I between AA 270 and 320. Protein Basic 
Local Alignment Search Tool (BLAST) alignment identified 96% homology for equine GnRHR-
I (National Center for Biotechnology Information; NCBI accession number NP_001075305.1) to 
the antibody epitope. Mouse testis protein, previously reported to express GnRHR-I (Bull et al., 
2000), was included in immunoblot analysis for GnRHR-I as a positive control. This antibody 
has been reported to successfully detect GnRHR-I in male rat thymus, rat ovary, human neurons, 
and human cancerous tissues (Keller et al., 2005; Szabó et al., 2005; Wilson et al., 2006; 
Sengupta et al., 2008; Su et al., 2013). 
A goat polyclonal antibody directed against GnRHR-II (sc-162889; Santa Cruz 
Biotechnology) was used to detect GnRHR-II protein in the stallion testis. This antibody was 
prepared against a synthetic human peptide derived between AA 60 and 75 of GnRHR-II. Using 
protein BLAST, the peptide corresponded to AA 147 to 162 of the predicted equine GnRHR-II 
protein (NCBI accession number XP_005610261.1). Protein BLAST software also identified 
89% homology between porcine GnRHR-II and the antibody epitope, while the equine GnRHR-
II maintained 86% homology to the antibody peptide. The validity of this antibody was 
confirmed via ELISA (Desaulniers et al., 2015).  
For detection of prepro-GnRH-I, a rabbit polyclonal antibody (sc-20941; Santa Cruz 
Biotechnology) was utilized. The epitope, AA 1 to 92, corresponded to the full-length prepro-
GnRH-I of human origin and was reactive against GnRH-I precursor, mature GnRH-I peptide, 
and GnRH-associated peptide-I (Santa Cruz Biotechnology). According to BLAST alignment, 
88% homology was retained from the antibody epitope to the predicted equine prepro-GnRH-I 
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hormone and 100% homology was retained for the mature GnRH-I peptide of equine origin 
(NCBI accession number XP_00364546.2). This antibody had previously been reported to detect 
GnRH-I in the female rat brain (Smarr et al., 2012) and mouse preoptic neurons (Szymanski and 
Bakker, 2012). 
To detect prepro-GnRH-II in the stallion testis, a rabbit polyclonal antibody (sc-20942; 
Santa Cruz Biotechnology) was utilized, which previously has been confirmed to detect GnRH-II 
in human ovarian cancer cells (Wilkinson et al., 2008). The immunogen used corresponded to 
AA 1 to 120 of the full-length prepro-GnRH-II hormone of human origin and was reactive 
against the GnRH-II precursor, the mature GnRH-II, and the GnRH-associated peptide-II (Santa 
Cruz Biotechnology). Alignment in Protein BLAST revealed 33% homology between the 
epitope and the predicted equine prepro-GnRH-II and 100% homology with the mature GnRH-II 
peptide of equine origin (NCBI accession number XP_005604572.1).  
Further validation for all primary antibodies included positive and negative control 
samples to verify antibody accuracy via Western blot technique (Table 2.2). To verify primary 
antibodies reacted to their specified peptide sequences in Western blot analysis, a testis tissue 
sample was collected from a species known to express the specific protein. Additionally, to 
confirm the antibody’s ability to recognize different concentrations of the specific protein, 3 
increasing protein levels were used. Finally, the secondary antibody was incubated with protein 
samples that did not contain the primary antibody to verify the secondary antibody did not 
interact with protein samples and provide false signal. 
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Table 2.2. Protein sources used as positive and negative controls to validate antibody specificity 
for the detection of GnRH-I and –II in the stallion testis using Western blot technique 
 Positive Control Negative Control 
GnRH-I Mouse Testis Mouse Bladder 
GnRHR-I Mouse Testis Boar Testis 
GnRH-II Boar Testis Mouse Testis 
GnRHR-II Boar Testis Mouse Testis 
 
 
 
 Immunoblot Analysis 
Protein was extracted from 400 mg of each testis sample via homogenization in 1 mL 
radioimmunoprecipitation assay (RIPA) buffer (20 mM Tris, 137 mM NaCl, 10% glycerol, 1% 
NP40, 0.1% SDS, 0.5% deoxycholic acid, 2 mM EDTA, 1 mM PMSF, 1% protease inhibitor 
cocktail and 1% phosphatase inhibitor cocktail) using a Biospec Tissue Tearor. A bicinchoninic 
acid assay (BCA; Pierce Biotechnology, Rockford, IL) was used to quantify extracted protein. A 
4X loading dye [2% Tris (pH 6.8), 28% glycerol, 20% SDS and Orange G] containing 
dithiothreitol (DTT; 100 mM) was mixed with each sample. Next, a 10% SDS-PAGE gel was 
used to separate 20 µg or 40 µg of each sample. This was followed by semi-dry electroblotting to 
an Immobilion-FL polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA). 
Membranes were incubated in Odyssey blocking buffer to block against non-specific binding for 
2 h at room temperature (RT). Membranes were incubated with a primary antibody directed 
against GnRHR-I (1:300; goat polyclonal; sc-8681; Santa Cruz Biotechnology) or GnRHR-II 
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(1:1000; goat polyclonal; sc-162889; Santa Cruz Biotechnology) by shaking at 4°C overnight 
(OVN). The primary antibody was diluted in Odyssey blocking buffer with 0.1% Tween-20.  
The following day, membranes were washed and incubated with a secondary donkey 
anti-goat antibody (1:20000; Alexa Fluor 680; Invitrogen, Carlsbad, CA). Secondary antibodies 
were diluted in Odyssey blocking buffer with 0.1% Tween-20 and 0.01% SDS and incubated 
with blots for 1 h at RT. Washes were performed with Tris-buffered saline with 0.1% Tween-20 
(TBS-T). Immunoblots were visualized with an Odyssey Scanner and Image Software (LI-COR 
Biosciences). Membranes were stained with GelCode® Blue Stain Reagent (Pierce Perbio 
Science Company, Rockford, IL) and destained with a 50% methanol and 1% acetic acid 
solution (Welinder and Ekblad, 2011). Blots were reimaged using an Odyessey Scanner to 
determine total protein in each lane. Total protein in each lane was used to normalize 
immunoblots. Normalized values were used to determine relative protein concentrations of 
GnRHR-I and GnRHR-II in the testicular tissue of all animals. 
 Immunodot Blot 
Protein was boiled for 5 min to denature proteins and expose epitope-binding sites. Then, 
1.6 µg of protein was applied directly onto a pre-wetted Immobilion-FL PVDF membrane and 
allowed to dry for 30 min. Saturated filter paper was used to keep the PVDF membrane hydrated 
while allowing protein to bind the membrane. Next, immunoblots were blocked against non-
specific binding by incubation in Odyssey Blocking Buffer for 2 h. Primary antibodies directed 
against GnRH-I preprohormone (1:150; rabbit polyclonal; sc-20941; Santa Cruz Biotechnology) 
and GnRH-II preprohormone (1:200; rabbit polyclonal; sc-20942; Santa Cruz Biotechnology) 
were used. Blots were incubated with primary antibody by shaking at 4°C OVN and then with 
secondary mouse anti-rabbit antibody (1:5000; Alexa Fluor 800; Invitrogen) for 1 h while 
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shaking at RT. Immunoblots were visualized with an Odyssey Scanner. Finally, immunoblots 
were stained for total protein as described previously.  
 Statistical Analysis 
Statistical analyses were performed on Western blot data using SAS (Version 9.2; Cary, 
NC). The General Linear Model (GLM) procedure was used to analyze immunoblot data with 
animal as the experimental unit and age as the fixed effect. Immunoblot data were confirmed to 
be normally distributed using the Shapiro-Wilk test. A P-value ≤ 0.05 was considered 
significant. Results are presented as means ± the standard errors of the mean (SEM). 
 Results 
 Sequencing Transcripts of GnRH Ligand and Receptor Isoforms in the Stallion Testis 
Utilizing gel electrophoresis, a band for each reverse transcription PCR (RT-PCR) 
product was identified in all animals (n = 15) at the expected product size for GnRH-I, GnRHR-
I, and GnRHR-II (Fig 2.1). The product generated with GnRH-I primers showed the most 
homologous match to predicted Equus caballus GnRH-I mRNA (NCBI accession number 
XM_003364498.2) with query coverage of 100%, an e-value of 6e-56, and maximum alignment 
identity of 100%. Alignment for the product generated with GnRHR-I primers revealed E. 
caballus GnRHR-I mRNA (NCBI accession number NM_001081836.1) as the optimal match 
with 100% query coverage, an e-value of 1e-42, and 94% alignment identity. The BLAST 
alignment for the GnRHR-II product identified 100% query coverage to the NCBI predicted E. 
caballus GnRH-II receptor-like mRNA (NCBI accession number LOC100065736) with an e-
value of 3e-158.  
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 Equine GnRH-II Retain Intron through Transcription 
Examination of the equine genome indicates the horse retains the GnRH-II precursor 
gene located on chromosome 22 (NCBI database; Stewart et al., 2009). However, researchers 
have not investigated the equine GnRH-II transcript. The predicted RT-PCR product size for 
equine GnRH-II was 200 base pair (bp), yet the RT-PCR product was approximately 350 bp 
(Fig. 2.1). Alignment for this product showed the greatest query coverage (100%) to predicted 
Equus przewaslkii GnRH-II mRNA (NCBI accession number XM_008527598.1). 
Comparatively, predicted E. caballus GnRH-II mRNA (NCBI accession number 
GnRHR-I 
L 
500 bp 
200 bp 
< 2 yr ! 2 yr 
GnRH-I 
L 
500 bp 
200 bp 
GnRHR-II 
L 
500 bp 
200 bp 
GnRH-II 
L 
500 bp 
200 bp 
< 2 yr ! 2 yr 
< 2 yr ! 2 yr < 2 yr ! 2 yr 
A C 
B D 
Figure 2.1. Representative agarose gels containing RT-PCR products generated from mRNA 
isolated from equine testicular tissue. The ladder is represented by L on each agarose gel. 
Primers were specific for GnRH-I, GnRH-II and their cognate receptor isoforms. Expected 
product size was observed for (A) GnRH-I [200 base pair (bp)], (B) GnRHR-I (200 bp), and (D) 
GnRHR-II (400 bp). The expected product size for (C) GnRH-II was 200 bp, however, the 
observed product size was 350 bp. 
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XM_005604515.1) had query coverage of only 40%. However, alignment of the sequenced 
product directly against the predicted E. caballus genomic GnRH-II gene (NCBI accession 
number NC_009165.2) showed 100% query coverage, an e-value of 6e-127, and 100% 
alignment identity (Fig 2.2). Thus it appears the horse retains the intron between exon 1 and exon 
2 through transcription of the GnRH-II gene and is transcribed differently than predicted by 
bioinformatics.  
 
 
  
  
Figure 2.2. (A) Model of intron and exon location of GnRH-II gene for E. przewaslki and E. 
caballus predicted by NCBI database. (B) Sequence comparison of the GnRH-II gene for E. 
przewaslki RNA, E. caballus DNA, and the sequenced product indicates predicted intron area 
(highlighted) is identical to the sequenced RT-PCR sample. (*indicates an identical sequence) 
Prez            CCAGAACACCCAGCATGCCCTTAGGCCCCCAGGTGGATGATGGGTTTCCTCAGCCTGAAT 60 
Horse           CCAGAACACCCAGCATGCCCTTAGGCCCCCAGGTGGATGATGGGTTTCCTCAGCCTGAAT 60 
Seq             CCAGAACACCCAGCATGCCCTTAGGCCCCCAGGTGGATGATGGGTTTCCTCAGCCTGAAT 60 
                ************************************************************ 
 
Prez            GAGAAGAAGAAAGTGCTGGCTGGGGCTCCTTCACCTACCTTGAGCCTTGGGTGGGGGTAG 120 
Horse           GAGAAGAAGAAAGTGCTGGCTGGGGCTCCTTCACCTACCTTGAGCCTTGGGTGGGGGTAG 120 
Seq             GAGAAGAAGAAAGTGCTGGCTGGGGCTCCTTCACCTACCTTGAGCCTTGGGTGGGGGTAG 120 
                ************************************************************ 
 
Prez            GGAGGGCAGGCTGCAGCCTCAGCTCTCTGCTGAGGAAGGATCCTGGGCACTGCAGCAAGC 180 
Horse           GGAGGGCAGGCTGCAGCCTCAGCTCTCTGCTGAGGAAGGATCCTGGGCACTGCAGCAAGC 180 
Seq             GGAGGGCAGGCTGCAGCCTCAGCTCTCTGCTGAGGAAGGATCCTGGGCACTGCAGCAAGC 180 
                ************************************************************ 
 
E. Przewaslki
E. Caballus 
Sequenced Product 
E. Przewaslki 
E. Caballus
Sequenced Product 
E. Przewaslki 
E. Caballus 
Sequenced Product 
Exon 1 Exon 2 
E. Przewaslki 
E. Caballus 
Exon 1 
A 
B 
  
41 
 Alternative Splicing of Equine GnRHR-II mRNA  
Several products were generated in the second PCR using nested primers to amplify 
GnRHR-II mRNA. Sequencing confirmed the product identity as E. Caballus GnRHR-II mRNA 
and provided clarification for unusual band sizes, as alternative splicing was discovered at the 
junction between exon 2 and 3 (Fig. 2.3). Splice variant 1 appeared to retain the entire 536 bp of 
the intron between exon 2 and 3. However, splice variant 2 retained only 196 bp of the intron and 
lacked 167 bp at the beginning of exon 3. Similar to splice variant 2, variant 3 also partially 
retained the intron; however, only 186 bp of the intron were retained and it lacked 174 bp of 
exon 3. Splice variant 4 deleted 75 bp from the terminal portion of exon 2 as well as 100 bp from 
the start of exon 3. If translated, equine GnRHR-II splice variants 1, 2, and 3 are each predicted 
to generate a 241 AA protein with a premature stop codon located 4 bp into the retained intron. 
Comparatively, a 235 AA protein was predicted for splice variant 4. Although variant 4 does not 
retain the intron between exon 2 and 3, this transcript still encodes a premature stop codon 61 bp 
into the retained portion of exon 3.  
In addition to alternative splice transcripts, sequencing of RT-PCR products also 
identified 2 transcripts spliced as predicted between exon 2 and 3. The first transcript was 
amplified from the 5’ end of exon 2 to the 3’ end of exon 3. Translation of this mRNA sequence 
predicts a 244 AA protein. This predicted protein was compared to known sequences in 
mammals reported to express the full-length GnRHR-II (Fig 2.4). A separate transcript amplified 
from the 5’ end of exon 1 to the 3’ end of exon 3 included ‘CACT’ at bp 649 in exon 2 (Fig 2.5). 
These 4 bases are encoded in E. Przewaslkii GnRHR-II mRNA (NCBI accession number 
XM_008528236.1), but they are not predicted to be included in the equine GnRHR-II mRNA 
(NCBI accession number XM_005610204.1). Translation of this product is predicted to generate 
a 220 AA protein. 
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Figure 2.3. A model indicating the relative position of the 3 exons and 2 introns for the predicted 
E. Caballus GnRHR-II gene sequence. Sequencing of RT-PCR products revealed several 
alternatively spliced transcripts for the equine GnRHR-II. A dashed line represents the intronic 
region that was removed as predicted. A solid line is representative of a transcribed intron, while 
a black box indicates a portion of an exon that was spliced out. Splice variant 1 retained intron 2 
through transcription, while splice variants 2 and 3 partially retained 196 or 186 bp of intron 2 as 
well as deleted 167 or 174 bp of exon 3 respectively. Splice variant 4, however, deleted 75 bp 
from exon 2 and 100 bp from exon 3. 
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Monkey          MSAGNGTPWGSAAGEESWAASGVAVEGSELPTFSAAAKVRVGVTIVLFVSSAGGNLAVLW 60 
Pig             MSAGNGTPLGSAVGEEVWAGSGVEVESSELPTFSVAAKVRVGVTVVLFVSSAGGNLAVLW 60 
R2e             MCAGNGTPWGSAAVEEVWGGSGVEMEDSELPTFSAAAKVRVGVTIVLFFSSAGGNLAVLW 60 
                *.****** ***. ** *..*** :*.*******.*********:***.*********** 
 
Monkey          SVTRPQPSQLRPSPVRTLFAHLAAADLLVTFVVMPLDATWNITVQWLAEDIACRTLMFLK 120 
Pig             SVTRPQPSQLRPSPVRRLFAHLAAADLLVTFVVMPLDASWNITVQWLAGDIACRTLMFLK 120 
R2e             SVTRPQPSQLSPSPVRRLFAHLAAADLLVTFVVTPLDATWNITVQWLAGDIACRTLIFLK 120 
                ********** ***** **************** ****:********* *******:*** 
 
Monkey          LMAMYSAAFLPVVIGLDRQAAVLNPLGSRSGVRKLLGAAWGLSFLLALPQLFLFHTVHRA 180 
Pig             LMAMYAAAFLPVVIGLDRQAAVLHPLGPRSGGRKLLGAAWLLSFLLALPQLFLFHTVRRA 180 
R2e             LMAIYAAAFLTMVIGLDRQAAVLHPLRPRSAGRKLLGAAWGLSFLLALPQLFLFHTVRRA 180 
                ***:*:****.:***********:** .**. ******** ****************:** 
 
Monkey          GPVPFTQCVTKGSFKARWQETTYNLFTFRCLFLLPLTAMAICYSHIVLSVSSPQTRKGSH 240 
Pig             GPVPFTQCVTKGSFKAQWQETTYNLFTFCCLFLLPLTVMTICYSRIVLSVSSPRTRKGND 240 
R2e             GPVSFTQCITKGSFKARWQETTYNLFSPSAAFFCCHYYDHLLQPHCPQCVQSPDKERELC 240 
                ***.****:*******:*********:  . *:       :  .:   .*.** ..:    
 
Monkey          APAGEFALCRSFDNCPRVRLWALRLALLILLTFILCWTPYYLLGLWYWFSPTMLTEVPPS 300 
Pig             APAGEFTLRRSLDNRPRVRLRALRLALLVLLTFVLCWTPYYLLGLWYWFSPTMLSEVPPS 300 
R2e             PCR--------------------------------------------------------- 243 
                .                                                            
 
Monkey          LSHILFLFGLLNAPLDPLLYGAFTLGCQRGHQELSIDSSNEG-SGRMLQQEIHALRQQEV 359 
Pig             LSHILFLFGLLNAPLDPLLYGAFTLGCRRRHQELSSDSSREGGSGRMHQQESQALRQMEV 360 
R2e             ------------------------------------------------------------ 
                                                                             
 
Monkey          QKTVTSRSAGETKDISITSI 379 
Pig             KTNAAARKAGKTKETFL--- 377 
R2e             -------------------- 
                                     
 
M. Mulatta 
S. Scrofa 
E. Caballus 
M. Mulatta 
S. Scrofa 
M. Mulatta 
S. Scrofa 
E. Caballus 
M. Mulatta 
S. Scrofa 
E. Caballus 
M. Mulatta 
S. Scrofa 
E. Caballus 
M. Mulatta 
S. Scrofa 
E. Caballus 
M. Mulatta 
S. Scrofa 
Figure 2.4. The amino acid sequence of GnRHR-II compared between Macaca mulatta, Sus 
scrofa, and E. caballus. The online transmembrane (TM) prediction tool, Tmpred, was used to 
predict TM domains which are indicated by boxes. GnRHR-II has 7 TM domains as indicated by 
M. mulatta and S. scrofa. However, a 244 AA protein with 5 TM domains is predicted to be 
translated from the equine transcript that spliced correctly between exon 2 and 3 and did not 
include 4 bases in exon 2. This transcript encodes a premature stop codon in exon 3. [(*) 
indicates an identical sequence, (:) represents an AA alignment with very similar properties, (.) 
represents an AA alignment with slightly similar properties] 
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 Protein Expression of GnRH Ligand and Receptor Isoforms in the Stallion Testis 
Immunodot blot analysis (Fig 2.6) was used to identify the presence of prepro-GnRH-I 
and prepro-GnRH-II protein in colts < 2 yr (n = 4) and stallions ≥ 2 yrs (n = 10), thus confirming 
that the GnRH-I and GnRH-II transcripts detected via RT-PCR are translated to protein within 
the stallion testis. The presence of both GnRHR-I and -II protein in the testis of all horses 
sampled was verified using immunoblot technique. However, colts < 2 yr (n = 4) had 3-fold 
greater GnRHR-I than stallions ≥ 2 yrs (n = 7; P < 0.022; Fig 2.7). Conversely, quantification of 
the relative band density of GnRHR-II protein indicated a trend for stallions ≥ 2 yr to have 
greater levels compared to colts < 2 yr (P = 0.0756; Fig 2.8). The approximate molecular weight 
of the GnRHR-II protein was approximately 55 kDa and the band for GnRHR-I was 50 kDa.  
 
 
Figure 2.5. Sequenced equine GnRHR-II product spliced as predicted between exon 2 and 
3, yet encoded 4 additional bases beginning at bp 649. Alignment via BLAST shows 99% 
homology of the predicted E. caballus GnRH-II Receptor-like mRNA to the predicted E. 
przewalskii GnRH-II Receptor-like mRNA. This transcript is predicted to only produce a 
protein with 220 AA and a stop codon (TGA) at 658 bp. (*indicates an identical sequence) 
horse           GGCCCAGTCTCCTTCACTCAATGTATCACCAAAGGCAGCTTCAAGGCTCGATGGCAAGAG 600 
Prez            GGCCCAGTCTCCTTCACTCAATGTATCACCAAAGGCAGCTTCAAGGCTCGATGGCAAGAG 600 
R2g             GGCCCAGTCTCCTTCACTCAATGTATCACCAAAGGCAGCTTCAAGGCTCGATGGCAAGAG 600 
                ************************************************************ 
 
horse           ACCACCTATAACCTCTTCTCACCTTCTGCTGCCTTTTTCTGCTGCCACT----ACTATGA 656 
Prez            ACCACCTATAACCTCTTCTCACCTTCTGCTGCCTTTTTCTGCTGCCACTCACTACTATGA 660 
R2g             ACCACCTATAACCTCTTCTCACCTTCTGCTGCCTTTTTCTGCTGCCACTCACTACTATGA 660 
                *************************************************    ******* 
 
horse           CCATCTGCTACAGCCGCATTGTCCTCAGTGTGTCCAGTCCCCAGACAAGGAAAGGGAACT 716 
Prez            CCATCTGCTACAGCCGCATTGTCCTCAGTGTGTCCAGTCCCCAGACAAGGAAAGGGAACT 720 
R2g             CCATCTGCTACAGCCGCATTGTCCTCAGTGTGTCCAGTCCCCAGACAAGGAAAGGGAACT 720 
                ************************************************************ 
 
E. przewalskii
E. caballus 
Sequence product 
E. przewalskii 
E. caballus 
Sequence product 
E. przewalskii 
E. caballus 
Sequence product 
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Figure 2.6. (A) Representative dot blots showing the 
presence of prepro-GnRH-I and (B) prepro-GnRH-II in the 
testis of colts < 2 yr and stallions ≥ 2 yr.  
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Figure 2.8. (A) Representative Western blot of testicular tissue from colts < 2 yr and stallions ≥ 
2 yr using an antibody directed against GnRHR-I. (B) Quantification of Western blots showed 3-
fold greater levels of GnRHR-I in colts < 2 yr compared to stallions ≥ 2 yr (P < 0.022). 
 
Figure 2.7. (A) Representative Western blot of testicular tissue from colts < 2 yr and stallions ≥ 
2 yr using an antibody directed against GnRHR-II. (B) There was a tendency for GnRHR-II to be 
produced in greater levels in stallions ≥ 2 than in colts < 2 yrs (P = 0.0756). 
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 Discussion 
Although previous researchers have identified GnRH-I and GnRHR-I in the testis of 
mature rats (Sharpe and Fraser, 1980; Botté et al., 1998), humans (Bahk et al., 1995), mice (Bull 
et al., 2000), alpacas (Zerani et al., 2011), and frogs (Pierantoni et al., 1984; Minucci et al., 
1986), very little is known regarding the role of the testicular GnRH-I:GnRHR-I complex. While 
production of GnRHR-I in mice and rats is greater after sexual maturity (Botté et al., 1998, 
Anjum et al., 2012), the current study provides the first evidence that GnRHR-I expression 
patterns differ in the stallion compared to other mammals. In equine testicular tissue, GnRHR-I 
protein levels were greater in colts < 2 yrs compared to stallions ≥ 2 yrs. Therefore, it appears 
GnRHR-I protein levels in the testis decrease as stallions age. The testicular GnRH-I complex 
may play a more important role in testicular development of pre-pubertal stallions compared to 
other mammals. 
The E. przewalskii species is the most ancient living relative to the modern horse, thus it 
is appropriate to compare its mRNA to that of E. caballus. The GnRH-II gene structures for E. 
przewalskii and E. caballus were predicted using bioinformatics to indicate the relative position 
of exons and introns. The E. przewalskii species is predicted to encode a single exon for GnRH-
II transcript (NCBI accession number XM_008527598.1). Comparatively, E. caballus is 
predicted to encode 2 exons separated by an intron with 140 bp (NCBI accession number 
XM_005604515.1). Sequencing of our RT-PCR product and BLAST alignment indicated that 
the equine transcribes the intron between bases 2102 and 2242 of the GnRH-II gene. A reverse 
transcription reaction with no reverse transcriptase confirmed there was no genomic DNA 
contamination in our samples. The sequenced product also has an identical alignment to the E. 
przewalskii GnRH-II mRNA. As E. przewalskii is not predicted to encode an intron in its GnRH-
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II mRNA, an identical alignment may indicate that the horse encodes a single exon for GnRH-II, 
similar to E. przewalskii, and is not as predicted via bioinformatics. 
It appears numerous species have coding errors in the GnRHR-II gene (Stewart et al., 
2009). Indeed, of the genomes examined thus far, only the pig, tree shrew, marmoset, and 
macaque retain a functional GnRH-II:GnRHR-II complex (Stewart et al., 2009). Previous 
researchers believed that the horse was unable to produce a functional GnRHR-II because of 
disruptive mutations in the gene (Stewart et al., 2009). The GnRHR-II gene in the horse is 
located on chromosome 5 and encodes the expected 3 exon/2 intron structure for the GnRHR-II 
gene similar to numerous other mammals (NCBI database). Researchers suggested that the 
equine encodes frameshifts in exon 2 and 3 with a premature stop codon located at codon 94 in 
exon 3 in the GnRHR-II (Stewart et al., 2009). We have shown that the GnRHR-II gene is 
transcriptionally active in the equine testis, as the presence of GnRH-II mRNA was confirmed 
via RT-PCR. 
Transcriptional regulation of GnRHR-II is poorly understood. Humans and sheep are 
reported to have coding errors in their GnRHR-II coding sequences (Morgan et al., 2003; Gault 
et al., 2004). However, it appears that the GnRHR-II gene is transcriptionally active in these 
mammals (Morgan et al., 2003; Gault et al., 2004). Based on our findings, the same appears to be 
true for the horse.  
Multiple splice variant transcripts were sequenced for GnRHR-II mRNA isolated from 
stallion testes. Alternatively spliced products of GnRHR-II also have been detected in the 
chicken and human (Morgan et al., 2003; Shimizu and Bédécarrats, 2006). Furthermore, it 
appears several GnRH receptor isoforms, including GnRHR-I (Kakar, 1997; Kottler et al., 1999) 
and GnRHR-III (Wang et al., 2001), generate multiple mRNA transcripts via alternative splicing. 
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Alternative splicing of the human GnRHR-II transcript circumvents a frameshift in exon 1 
(Morgan et al., 2003). As a result of this splicing, a 5 TM receptor may be produced in the 
human (Neill, 2002). In the human and chicken, there was no intron retention in the GnRHR-II 
variant transcripts. However, the bullfrog GnRHR-III gene is reported to exhibit spliced 
transcripts that retain a portion of intron 2 (Wang et al., 2001). Similar to what has been observed 
in the bullfrog, we also sequenced several transcripts that showed intron retention of the equine 
GnRHR-II gene. Yet, splice variants in the equine that retained the intron portion introduced a 
premature stop codon that would produce a truncated protein with 241 AA.  
 While multiple equine GnRHR-II transcripts were sequenced, these transcripts were 
predicted via an online translation tool to generate truncated proteins. However, we detected a 
large protein using Western blot. The molecular weight of GnRHR-II in the boar testis, which 
was incorporated as a positive control in this study, is 60 kDa (Desaulniers et al., 2015), whereas 
our data revealed a molecular weight of 55 kDa using an antibody specific to GnRHR-II. The 
differently sized products of GnRHR-II may be the result of differing glycosylation or a 
truncated protein.  
 Reseachers have suggested a full-length GnRHR-II may be produced in the human (Neill 
et al., 2004). Although a frameshift and premature stop codon are documented in the human 
genome, there is precedence for a functional human GnRHR-II (Neill et al., 2004). In human 
cancer cells where GnRHR-I was suppressed, the administration of GnRH-II still showed anti-
prolific effects; thus GnRH-II may be acting via GnRHR-II (Gründker and Emons, 2003). 
Even though the horse appears to encode frameshifts and a premature stop codon, post-
transcriptional mechanisms may be employed in the equine testis to produce the full-length 
GnRHR-II protein that was detected via Western blot. Suppression of premature stop codons has 
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been reported in numerous mammalian genes (Robinson and Cooley, 1997). Rather than 
translation of the stop codon, UGA is translated as a selenocysteine (Low and Berry, 1996). 
Moreover, RNA editing may also recode or repair frameshifts in GnRHR-II transcript, thus 
allowing a full-length receptor to be translated (Namy et al., 2004). Post-transcriptional 
modification of the GnRHR-II transcript is a potential mechanism to overcome coding errors and 
allow the horse to generate a full-length, potentially functional receptor.  
The numerous other effects reported for GnRH-II, such as regulation of female 
reproductive behavior, feed intake, gonadotropin release, and anti-prolific effect on cancerous 
tissues, are likely caused by GnRH-II binding GnRHR-I. Evidence from the boar is the first to 
indicate an effect of GnRH-II binding its cognate receptor and eliciting a response (Desaulniers 
et al., 2015). The boar does not express GnRHR-I in the testis (Zanella et al., 2000), thus it is 
thought GnRH-II interacts solely with GnRHR-II. However, as the stallion expresses both 
receptor and ligand isoforms in the testis, the potential functions of GnRH-I and -II increase with 
their ability to bind the other’s receptor and illicit separate responses. To date, the stallion is the 
only other mammal, in addition to the human, that has been identified to potentially express both 
ligand and receptor isoforms in the testis (Neill et al., 2001; Neill, 2002; Neill et al., 2004).  
Indeed, the intricacies of equine autocrine and paracrine regulation of steroidogenesis and 
spermatogenesis in the stallion testis are very complex. As reviewed by Roser (2008), numerous 
hormones are produced in the testis to modulate the microenvironment and aid germ cell 
development. Hormones known to be produced in the stallion testis include androgens, 
estrogens, inhibin, activin, insulin-like growth factor-1, transferrin, insulin like peptide 3, β-
endorphins, and oxytocin (Roser, 2008). To this list, GnRH isoforms -I and -II can now be 
included, however their physiological effects are still unknown in the stallion.  
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The current study is the first to establish GnRH-I and GnRHR-I mRNA and protein are 
produced in the stallion testis. The equine genome has been examined for GnRH-II and GnRHR-
II genes and bioinformatics has predicted the potential mRNA transcripts of these genes. 
However, we are the first to report that the GnRH-II and GnRHR-II genes are transcriptionally 
active and translated into protein within the stallion testis. Therefore, the presence of GnRH-I 
and GnRH-II and their cognate receptors in the stallion testis infers a possible autocrine and/or 
paracrine function of these decapeptide hormones to assist in steroidogenesis and/or 
spermatogenesis.  
These discoveries may have implications in developing novel pharmacologic agents for 
the treatment of sub-fertility or infertility in stallions, as researchers suggest a pivotal role for 
GnRH-I and GnRH-II in male reproduction. Additionally, detection of the GnRH-II complex 
within the stallion testis may provide insight into why current GnRH vaccines do not consistently 
suppress sperm production in stallions. The inclusion of GnRH-II in GnRH vaccines may 
improve male contraceptive methods and assist in the control of wild horse populations. Further 
research is required to fully elucidate the localization and function of GnRH-I and -II and their 
cognate receptors in the equine testis. 
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Chapter 3 - GnRHR-II Detected on Ejaculated Equine Spermatozoa 
 Introduction 
Spermatogenesis is the process whereby spermatogonial germ cells develop into 
spermatozoa in seminiferous tubules. The seminiferous tubules, in turn, contain both germ cells 
and Sertoli cells. Within seminiferous tubules, basal and adluminal compartments are formed via 
tight junctions between Sertoli cells. These tight junctions form the blood-testis barrier, isolating 
germ cells from the interstitial tissue. The purpose of the blood-testis barrier is to provide a 
microenvironment conducive to germ cell development and to prevent an autoimmune response 
of the body to its own germ cells (Senger, 2012).  
There are 3 major stages of spermatogenesis: proliferation, meiosis, and differentiation. 
Proliferation occurs in the basal compartment of seminiferous tubules and results from mitotic 
divisions of spermatogonial germ cells. Meiosis and differentiation take place in the adluminal 
compartment. Primary spermatocytes are haploid cells that are produced from meiosis 1. To 
increase genetic diversity, crossing over of DNA occurs in secondary spermatocytes and results 
in spermatozoa that encode unique nuclear DNA (Johnson et al., 1997). 
Next, spermatids differentiate via spermiogenesis into highly specialized spermatozoa. 
Spermatozoa are comprised of a head that stores nuclear material and a flagellum that includes a 
midpiece and principal piece. Upon differentiation, spermatozoa are released into the lumen of 
the seminiferous tubule where they migrate to the epididumal caput (Johnson et al., 1997). 
Spermatozoa mature as they migrate through the epididymis. During maturation the cytoplasmic 
droplet is removed from the midpeice and the spermatozoa become progressively motile 
(Johnson et al., 1997; Senger, 2012).  
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The GnRH isoforms, GnRH-I and GnRH-II, along with their receptors, have been 
detected in seminiferous tubules of several mammals (van Biljon et al., 2002; Ramakrishnappa et 
al., 2005; Ciaramella et al., 2015; Desaulniers et al., 2015). Like GnRH-I, GnRH-II, has been 
isolated in the testis of humans (van Biljon et al., 2002), boars (Desaulniers et al., 2015), and our 
previous work in stallions. Receptors for both GnRH-I and GnRH-II (GnRHR-I and GnRHR-II) 
have been localized to spermatogenic cells throughout several stages of spermatogenesis in 
seminiferous tubules (Ciaramella et al., 2015; Desaulniers et al., 2015).  
In terms of function, several roles for GnRH-I have been postulated that affect 
spermatogenesis. In the rat and mouse, GnRHR-I has been identified on spermatogonial germ 
cells and elongated spermatids (Ciaramella et al., 2015), while, in the human, GnRHR-I has been 
detected on ejaculated spermatozoa (Morales et al., 2002). Because both GnRH-I and GnRHR-I 
are expressed in the same cell type during acrosome biogenesis, it has been postulated that 
GnRH-I may function through an autocrine mechanism during this stage of spermatogenesis 
(Ciaramella et al., 2015). As well, it has been suggested that GnRH-I secreted from Sertoli cells 
functions via paracrine signaling to assist in sperm release from seminiferous tubules and 
transport to the epididymal caput (Ciaramella et al., 2015). The percentage of ejaculated human 
spermatozoa that bind to the zona pellucida is increased when incubated with a GnRH-I agonist, 
thus GnRH-I may interact with its receptor to facilitate spermatozoa binding (Morales et al., 
2002). 
Similarly, GnRHR-II has been detected in human and porcine spermatogonial germ cells. 
Transcripts for GnRHR-II have been isolated from ejaculated human spermatozoa (van Biljon et 
al., 2002). In the boar, GnRHR-II has been localized to the membrane of germ cells and the 
  
54 
connecting piece of mature ejaculated spermatozoa (Desaulniers, 2013; Desaulniers et al., 2015). 
Although GnRHR-II is clearly present in germ cells, its function is poorly understood. 
Previously, we detected GnRHR-I and GnRHR-II mRNA transcripts and protein 
expressed locally in the stallion testis (Chapter 2). Because localized GnRHR-I and GnRHR-II in 
mammalian spermatogenic cells may play an important role in the maturation of spermatozoa 
and in their ability to fertilize an ovum, our next objective was to determine whether these 
receptor isoforms are present on ejaculated equine spermatozoa.  
 Materials and Methods 
 Collection and Purification of Equine Spermatozoa 
Using standard industry practices, semen was collected from 6 Quarter Horse stallions (9 
to 18 yr) via a Missouri model artificial vagina equipped with a collection bottle and gel filter. 
After collection, semen was transferred to a 50 mL conical tube where 1 mL of semen was 
layered on 6 mL of EquiPureTM (Nidacon, Healdsburg, CA) and centrifuged at 300 x g for 30 
min at room temperature (RT). The EquiPureTM solution was removed and the purified sperm 
pellet was rinsed by centrifugation with phosphate buffered solution (PBS; Life Technologies, 
Grand Island, NY) at 300 x g for 10 min. Next, PBS was removed and each sample was diluted 
in 1 mL of fresh PBS. A drop of diluted sperm was air-dried on an UltraStick slide (Gold Seal 
Products, Portsmouth, NH) for immunocytochemistry. Purified sperm were also flash frozen in 
liquid nitrogen for protein extraction and immunoblot analysis. Remaining semen was 
centrifuged for 10 min at 300 x g to separate seminal plasma, which was then removed and 
stored at -20°C. Four semen samples were used for immunoblotting and 4 semen samples were 
used for immunocytochemistry. 
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 Immunoblot 
To extract protein from spermatozoa, 400 µL of RIPA buffer (20 mM Tris, 137 mM 
NaCl, 10% glycerol, 1% NP40, 0.1% SDS, 0.5% deoxycholic acid, 2 mM EDTA, 1 mM PMSF, 
1% protease inhibitor cocktail and 1% phosphatase inhibitor cocktail) was added to purified 
spermatozoa, which were then passed through a 21 gauge needle followed by a 27 gauge needle. 
Samples were incubated in RIPA buffer for 90 min on ice. The protein in each sample was 
quantified using a bicinchoninic acid (BCA) assay kit (Pierce Biotechnology, Rockford, IL). A 
4X loading dye [2% Tris (pH 6.8), 28% glycerol, 20% SDS and Orange G] containing 
dithiothreitol (DTT; 100 mM) was mixed with each sample. Twenty µg of protein was then 
separated on a 12% SDS-PAGE gel. This was followed by semi-dry electroblotting to an 
Immobilion-FL polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA). 
Membranes were incubated with Odyssey blocking buffer for 2 h at RT to block against non-
specific binding. Immunoblots were probed with a goat polyclonal antibody directed against 
GnRHR-II (1:750; sc-162889; Santa Cruz Biotechnology, Santa Cruz, CA) and GnRHR-I 
(1:300; sc8681; Santa Cruz Biotechnology) diluted in Odyssey blocking buffer with 0.1% 
Tween-20. Blots were incubated with primary antibody by shaking at 4°C overnight (OVN). The 
following day, membranes were incubated with a secondary donkey anti-goat antibody (1:20000; 
Alexa Fluor 680; Invitrogen, Carlsbad, CA) in Odyssey blocking buffer with 0.1% Tween-20 
and 0.05% SDS for 1 h at RT. Following primary and secondary antibody incubation, 
membranes were washed in Tris-buffered saline with 0.1% Tween-20 (TBS-T). Immunostaining 
was visualized with an Odyssey Scanner and Image Software (LI-COR Biosciences). To 
determine total protein in each lane, membranes were stained with GelCode® Blue Stain Reagent 
(Pierce Perbio Science Company, Rockford, IL) and destained with a 50% methanol and 1% 
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acetic acid solution (Welinder and Ekblad, 2011). Blots were then reimaged using an Odyssey 
Scanner. 
 Immunocytochemistry 
Sperm were fixed to an UltraStick slide with 4% paraformaldehyde at RT in a humidified 
chamber. Once sperm were fixed, the slides were rinsed in TBS. Autofluorescence was abolished 
with a 30 min exposure to ultraviolet light. Slides were incubated in TBS-T (0.5% Tween-20) for 
10 min at RT to permeablize spermatozoa. To remove excess TBS-T, slides were then rinsed 
with TBS. A 10% normal serum diluted in TBS-T (0.05% Tween-20) was incubated with the 
slides for 30 min at RT to reduce non-specific binding. After blocking, slides were treated with 
either a monoclonal mouse primary antibody directed against GnRHR-II (1:25, sc-100301, Santa 
Cruz Biotechnology) or a polyclonal goat primary antibody directed against GnRHR-I (1:25; sc-
8681; Santa Cruz Biotechnology) diluted with 10% normal serum in TBS-T (0.05% Tween-20) 
and incubated OVN at 4°C.  
The next morning, excess primary antibody was removed with 3 washes in TBS-T 
(0.05% Tween-20). Slides were treated with an Alexa Fluor 488 secondary antibody (rabbit anti-
goat or goat anti-mouse; Invitrogen) for 1 h at RT in a dark, moist chamber. The secondary 
antibody was diluted 1:400 in 10% normal serum TBS-T (0.05% Tween-20). Finally, slides were 
rinsed with TBS-T (0.05% Tween-20) to remove residual antibody. An 80% glycerol and 20% 
Tris mounting solution was utilized to seal the slides. An inverted confocal microscope 
(Olympus IX 81) with FITC filter sets was utilized at the University of Nebraska-Lincoln 
microscopy core to view the spermatozoa. 
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 Results and Discussion 
While GnRHR-I was not detected in purified stallion sperm protein via Western blot 
analysis nor immunocytochemistry using the sc-8681 antibody directed against GnRHR-I, we 
identified a 55 kDa band for GnRHR-II using immunoblot (Fig 3.1). A similar molecular weight 
was reported for GnRHR-II isolated in purified boar spermatozoa (Desaulniers et al., 2015) and 
equine testicular tissue (Chapter 2). Furthermore, GnRHR-II was localized to the neck region of 
mature purified equine spermatozoa through the use of immunocytochemistry (Fig 3.2). The 
GnRHR-II has also been detected at the same location on the connecting piece of mature boar 
spermatozoa while GnRH-II was also identified in boar seminal plasma (Desaulniers, 2013). It is 
thought that in boars the GnRH-II complex may play a role in motility or tail development 
(Desaulniers, 2013).  
In contrast, GnRHR-I has been identified on spermatogenic cells of rats, mice and 
humans (Morales et al., 2002; Ciaramella et al., 2015). Depending on the stage of development, 
multiple functions have been postulated for the GnRH-I complex. Even though we previously 
detected GnRHR-I in the testis of stallions, this receptor appears to be absent on mature stallion 
spermatozoa. Identifying the exact location of GnRHR-I within the testis may elucidate the 
presence of GnRHR-I on immature spermatogenic cells or other testicular cells.  
Although we are the first to identify GnRHR-II protein on stallion spermatozoa via 
immunoblot and immunocytochemistry, the significance of this finding is unclear. Because of 
the localization of GnRHR-II to the connecting piece of equine spermatozoa, GnRH-II may have 
numerous functions including assisting fertilization, increasing motility, and assisting in 
capacitation. In the human, GnRHR-I has been reported to assist sperm binding to the zona 
pellucida (Morales et al., 2002). As GnRHR-I was not present on equine spermatozoa, GnRHR-
II may have a similar function in the stallion. Because mitochondria located in the midpiece 
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enable the whipping motion of the tail and subsequent motility of spermatozoa, GnRH-II may 
also play a role in progressive motility. Sperm capacitation requires calcium release (Ho and 
Suarez, 2003). Intracellular stores of calcium are located near the redundant nuclear envelope in 
the neck region of sperm (Ho and Suarez, 2003). These stores of calcium may be released as a 
result of GnRH-II binding GnRHR-II on the connecting piece of stallion spermatozoa and assist 
capacitation.  
While GnRHR-II was detected on stallion spermatozoa, we did not analyze stallion 
seminal plasma for the presence of GnRH-II. Furthermore, GnRHR-II mRNA has been identified 
in the female reproductive tract of the human and marmoset (Neill et. al., 2001; Millar et al., 
2001). Additional research investigating the presence of GnRH-II in stallion seminal plasma and 
the mare reproductive tract may elucidate potential functions for the GnRH-II complex in 
stallion reproduction. Identifying the role of GnRHR-II on spermatozoa may have implications 
for increasing post-thaw motility of frozen semen, and improving conception rates of sub-fertile 
stallions by increasing the percentage of motile sperm after storage.   
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Figure 3.1. Representative Western blot of purified 
stallion spermatozoa protein using the GnRHR-II 
antibody sc-162889 (Santa Cruz Biotechnology). 
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Figure 3.2. Representative confocal microscopy images of purified stallion spermatozoa using 
an antibody directed against GnRHR-II (sc-100301) labeled with an Alexa Fluor 488 secondary 
antibody. Panel A shows green fluorescence, B shows brightfield, and C represents an image 
merged with both fluorescence and brightfield. A secondary only control is shown by panels D-
F.  
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Appendix A - Utilizing Fecal pH to Predict Cecal pH in the Equine 
 Introduction 
Equine digestive disorders including, colic, hindgut acidosis, and laminitis, are 
detrimental to the horse and the entire equine industry. Treatment of these diseases can be 
challenging and expensive. Thus, preventative measures often implemented through dietary 
management, are often the best strategy for dealing with these ailments. Cecal cannulation is can 
be used for direct assessment of cecal pH in equines. However, collecting cecal material requires 
cannulation or post-mortem sample collection. While cecal cannulation allows access to the 
cecum, this surgery is expensive and invasive.  
Analysis of fecal material is considered 1 of few viable methods for monitoring digestive 
health in intact horses (Berg et al., 2005; Vörös et al., 2009; Berg et al., 2013, as collecting 
digesta directly from the gastrointestinal tract can be challenging. Therefore, analysis of volatile 
fatty acids, pH, and microbial content of fecal material this is often used to represent the hindgut 
environment (Berg et al., 2005). Indeed, analysis of fecal material has been used to assess 
colonic health in rats (Campbell et al., 1997), pigs (Howard et al., 1995), and humans (Benno 
and Mitsuoka, 1992). Even though analysis of fecal material is commonly utilized to represent 
the hindgut environment of the equine, few researchers have investigated the true relationship 
between cecal and fecal material. In this retrospective study, we assessed the association between 
fecal pH and cecal pH and attempted to develop a predictive equation for cecal pH. 
 Materials and Methods 
Management 
Nine cecally cannulated Quarter horses were utilized. The group was comprised of 5 
geldings and 4 mares, aged 8 to 10 yr, and body weight ranging from 455 to 590 kg. Horses were 
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housed in heated individual stalls with ad libitum access to water and white salt blocks. They 
were fed 1.5% BW prairie grass hay split into twice daily feedings (0700 and 1930) and 0.5% 
BW concentrate (Omolene 200, Purina Animal Nutrition, LLC, Gray Summit, MO) which was 
fed in the mornings only (0700). Horses were maintained on this diet for 3 separate 21-d periods. 
Cecal and Fecal Collection 
Cecal and fecal pH were measured on d 19 to 21 of each period at -1, +1, +4, +8, +12, 
+16, +20, and +24 h relative to feeding the concentrate meal (Figure A.1). Fecal and cecal 
samples were collected concurrently from each horse at each timepoint. While biosamples were 
collected, horses were restrained in stocks. Cecal fluid was obtained from the cannula via gravity 
directly into sterile collection cups and filtered through a layer of cheesecloth to remove large 
particles. Cecal pH was immediately measured by immersing a pH probe (Thermo Scientific 
orion 3 Star Portable pH Meter, Waltham, MA; Accument probe) directly into the cecal fluid. 
Once a stable reading was established, the measurement was recorded.   
Fecal samples were retrieved via the rectum and placed into sterile collection cups. Equal parts 
deionized water and fecal material were included in a sterile collection cup and homogenized. A 
pH reading was then recorded for the homogenous mixture. Between each horse, cecal, and fecal 
measurements, the pH probe was rinsed in deionized water. 
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Statistical Analysis 
Given inherent animal-to-animal variability in the pH dynamics of the cecum and rectum 
over time, the minimum cecal pH observed after feeding was utilized for each animal-day 
combination and modeled as a function of the corresponding minimum fecal pH using a general 
linear mixed model. Kenward-Roger’s procedure was used to estimate degrees of freedom and to 
make the corresponding adjustments in estimated standard errors. The model was fitted using the 
GLIMMEX procedure of Statistical Analysis Software (SAS; Version 9.2; SAS Institute, Cary, 
NC). 
 Results and Discussion 
There was a moderate association between minimum cecal pH and minimum fecal pH (P 
= 0.03; Figure A.2). The estimated rate of change for minimum cecal pH per unit increase in 
minimum fecal pH was 0.131 with a 95% confidence interval of 0.011 to 0.251. The prediction 
equation for estimated cecal pH was Y = 0.131*X + 5.8969, where X was the observed fecal pH. 
However, the amount of predictive variability was considerable. Multiple factors alter the 
transit time of digesta from cecum to rectum, including feed composition, animal weight, and 
physiological state. Indeed, there was a -0.059 correlation coefficient for actual cecal pH vs 
predicted cecal pH (Figure A.3). This indicates there is no relationship between actual cecal pH 
and the estimated cecal pH generated via prediction equation. 
0600 0700 0800 1100 1500 1900 2300 0630 0300 1930 
-1* 
AM meal 
+1 +4 +8 +12 +16 +20 +24 
PM meal 
Time: 
Hour relative 
to AM meal: 
Figure A.1. Timeline depicting cecal and fecal sampling protocol. Arrows depict times of 
sampling on d 19 to 21; *d 19 only 
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Although analysis of fecal material has been used to assess the colonic environment of 
other monogastrics, analysis of equine fecal material may not accurately reflect what is occurring 
in the cecal environment. Horses differ greatly from monogastric mammals, as they are hindgut 
fermenters. Based on the data available and these analyses, it appears fecal pH has limited 
usefulness in predicting cecal pH. 
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Minimum post-prandial fecal pH Figure A.2. Minimum post-prandial cecal pH plotted against minimum post-prandial 
fecal pH for each horse on each day (n = 81). Analysis revealed evidence for an 
association between minimal cecal pH and minimal fecal pH (P = 0.03). 
 
  
81 
 
!"!#$
!"%&$
!"%'$
!"%($
!"%!$
!"%#$
!"#&$
!"#'$
!"#($
!"#!$
!"##$
!")&$ !"(&$ !"*&$ !"!&$ !"%&$ !"#&$ !"+&$ %"&&$ %",&$ %"'&$ %")&$
P
re
d
ic
te
d
 c
ec
a
l 
p
H
 
Actual cecal pH 
Predicted cecal pH vs actual cecal pH recorded 
Figure A.3. Using the prediction equation generated, this graph represents predicted 
cecal pH vs. actual cecal pH recorded. A 4 h time lag between minimal cecal and 
minimal fecal pH values was detected (Delano et al., 2014). Therefore, fecal pH at 12 
h post-prandially was utilized in the prediction equation to estimate cecal pH at 8 h 
post-prandially for each horse on each day. The correlation coefficient for actual 
cecal pH vs predicted cecal pH was -0.059. 
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Appendix B - Supplemental Data 
 
 
 
 
A 
B 
Figure B.1. (A) Full GnRH-I dot blot with extracted equine testicular protein (n = 18) from 
Chapter 2. The first sample is a positive control (mouse testis) followed by a negative control 
sample (mouse bladder). (B) Total protein stain from the above blot was used to confirm protein 
was present on the membrane.  
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A 
B 
Figure B.2. (A) Antibody validation 
of GnRH-I antibody (sc-20941; 
Santa Cruz Biotechnology) with 
decreasing protein concentrations 
(1600, 800, 400 ng/µL protein).    
(B) Total protein stain from the 
above blot. 
  
84 
 
 
Figure B.3. Membrane 
incubated in only the 
secondary antibody (mouse 
anti-rabbit; 1:5000; Alexa 
Fluor 800; Invitrogen) to 
verify the secondary 
antibody did not interact 
with protein samples and 
provide fase signal. 
Samples include positive 
control (mouse testis), 
negative control (mouse 
bladder), and protein 
collected from the horse 
testis. No signal was 
detected. 
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Figure B.4. (A) Full GnRH-II dot blot with extracted equine testicular protein (n = 18) from 
Chapter 2. The first sample is a positive control (boar testis) followed by the negative control 
sample (mouse bladder). (B) Total protein stain from the above blot was used to confirm protein 
was present on the membrane. 
A 
B 
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A 
B 
Figure B.5. (A) Antibody 
validation of the GnRH-II 
antibody (sc-20942; Santa Cruz 
Biotechnology) with decreasing 
protein concentrations (400, 
200, 100 ng/µL protein). (B) 
Total protein stain from the 
above blot. 
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Figure B.6. Membrane 
incubated in only the 
secondary antibody (mouse 
anti-rabbit; 1:5000; Alexa 
Fluor 800; Invitrogen) to 
verify the secondary 
antibody did not interact 
with protein samples and 
provide fase signal. 
Samples include positive 
control (boar testis), 
negative control (mouse 
testis), and protein collected 
from the horse testis. No 
signal was detected. 
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A 
B 
Figure B.7. (A) Western blot of testicular tissue from colts < 2 yr (n = 4) and 
stallions ≥ 2 yr (n = 7) using an antibody directed against GnRHR-I. These blots 
were replicated 3 times. The first lane includes a negative control sample (boar 
testis) and the second lane includes a positive control sample (mouse testis). The 
third lane contained the pre-stained ladder. (B) Total protein stain from the above 
blot was used to confirm protein was present on the membrane. 
  
89 
  
A 
B 
Figure B.8. (A) Antibody validation of 
GnRHR-I antibody (sc-8681; Santa Cruz 
Biotechnology) with increasing protein 
concentrations (10, 20, 40 µg/µL 
protein). The forth lane includes positive 
control (mouse testis) and fifth lane 
includes negative control (boar testis). 
(B) Total protein stain from the above 
blot was used to confirm protein was 
present on the membrane. 
  
90 
 
A 
B 
Figure B.9. (A) Western blot of testicular tissue from colts < 2 yr (n = 4) and stallion 
≥ 2 yr (n = 7) using an antibody directed against GnRHR-II. These blots were 
replicated 3 times. The first lane contains the pre-stained ladder. The second lane 
includes a positive control sample (boar testis) and the third lane includes a negative 
control sample (mouse testis). Only the largest band detect was quantitated to total 
protein. (B) Total protein stain from the above blot was used to confirm protein was 
present on the membrane. 
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A B 
Figure B.10. Membrane was 
incubated in only the secondary 
antibody (donkey anti-goat; 
1:20000; Alexa Fluor 680; 
Invitrogen) with horse testis 
protein to verify the secondary 
antibody did not interact with 
protein samples and provide fase 
signal. The same secondary 
antibody was utilized for both 
GnRHR-I and -II antibodies. 
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A B 
C 
Figure B.11. Representative confocal microscopy images of purified bull spermatozoa (n = 1) 
using an antibody directed against GnRHR-II (sc-100301) labeled with an Alexa Fluor 488 
secondary antibody. Panel A shows green fluorescence, B shows brightfield, and C represents an 
image merged with both fluorescence and brightfield. This bull sample was included as a 
negative control to verify antibody specificity. 
